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4Abstract
Amyotrophic lateral sclerosis (ALS) is an adult‑onset, rapidly progressive and ultimately 
fatal neurodegenerative disorder characterised by degeneration of upper and lower 
motor neurons. This leads to weakness, muscular atrophy and spasticity, which 
relentlessly progress to complete paralysis with a low survival rate beyond 5 years 
from symptom onset. In 10% of cases the disease is considered to be genetically 
transmitted (FALS) while in the remaining cases it occurs sporadically in the population 
(SALS). To date, cases of hereditary ALS have been attributed to mutations in more 
than 16 different genes, the most common being SOD1, FUS, TARDBP and C9ORF72; 
mutations in other genes are rare. The above genes explain 60% of the cases of 
familial ALS and 15% of sporadic cases.
The disease can be subdivided into bulbar (25%) and spinal‑onset (75‑80%) forms. 
Nevertheless, it is currently recognized that pathological changes are not limited to 
the motor system: patients with ALS may exhibit cognitive abnormalities ranging from 
impaired frontal executive dysfunction to overt frontotemporal dementia (FTD).
In spite of the above evidence, ALS is regarded as a complex disease in which multiple 
environmental and genetic risk factors contribute to disease susceptibility. Furthermore 
it is possible that the phenotypic variability, which is frequently detected within families, 
could be due to multiple genetic factors as devised in the oligogenic disease model.
In the present study we analysed 285 SALS and 17 FALS cases. Globally, our 
molecular analysis explained 10.3% of all ALS cases (31/302). The genes screened 
were SOD1, TARDBP, FUS and C9ORF72. Genomic DNA was extracted from 
peripheral blood through a salting out procedure; coding regions and exon‑intron 
boundaries of SOD1 (5 exons), TARDBP (1 exon), and FUS (5 exons) genes were 
amplified from genomic DNA and sequenced. Otherwise the repeat‑primed PCR 
assay, used for C9ORF72 gene, was performed in order to screen for the presence 
of the GGGGCC hexanucleotide repeats expansion in ALS patients. The repeat 
unit of 6 nucleotides expands up to more than several hundred times in the affected 
individuals. Fewer than 10 repeats are not associated with a pathological phenotype, 
while more than 30 repeats are associated. However we still do not know the meaning 
5of intermediate repeat sizes (11‑29). This fact complicates the attribution of the size 
expansion to the pathological phenotype observed.
According to the oligogenic disease model, all patients were screened for the most 
common ALS‑associated genes and all mutated subjects were tested also for ANG. 
The affected/unaffected family members, when available for the study, were screened 
for SOD1, TARDBP, FUS and C9ORF72 in order to identify their genetic difference 
from the proband and to evaluate if this difference could explain an heterogeneous 
phenotypic expression of the disease.
Following these analyses we selected and described in detail 5 FALS and 2 SALS 
cases and one SETX case, with different intrafamilial phenotypic expression. In one 
of our SOD1 mutation carriers, the proband manifested the disease after the delivery; 
together with a specific angiogenin genetic variant this condition seems to have 
anticipated the age of disease onset and contributed to the aggressive clinical course 
observed in the proband compared to other family members. We also found one case 
in which we observed the phenomenon of anticipation, which could be due to hormonal 
treatments together with the simultaneous presence of 2 mutations (C9ORF72/
TARDBP), as suggested in the oligogenic disease model. Indeed, the neuroprotective 
effects of estrogens could account for the later age at onset in women as we have 
tested in another family harbouring the R521C mutation. In this case a male subject 
developed the disease, whereas his older sister didn’t show any neurological signs. 
In another family we observed a wide spectrum of clinical symptoms associated 
with A382T TARDBP mutation. Some family members showed cognitive impairment 
without signs of ALS, conversely, other relatives showed a typical ALS without any 
signs of dementia. In addition we have evidence of TARDBP mutation carriers without 
a neurological phenotype. Surprisingly, two subjects harbouring the mutation in 
homozygous state display different spectra of clinical symptoms. The screening of 
SOD1, FUS, C9ORF72 and ANG in the family members, to identify other mutations 
that could explain this intrafamilial phenotypic heterogeneity, resulted negative; 
indicating that other genes/conditions could play a role in ALS disease.
These data support the hypothesis that phenotypic variability seen in patients carrying 
the same mutation, could be attributed to additional genetic and/or environmental 
factors, which could modify the penetrance of the disease. Furthermore we identified a 
6clinical subgroup of patients that develop the disease during pregnancy (child‑bearing 
age), thus indicating an additional modifier conditions linked to hormonal changes. 
For all these reasons predictive or presymptomatic testing should be undertaken 
with caution, especially in unaffected family members. Indeed, it is impossible for the 
genetic test to predict clinical outcomes based on the genotypic results only. A number 
of uncertainties remain, due to variability in penetrance, expressivity, and modifying 
factors, such as gene‑gene interactions and environmental influences. This adds to 
the debate for the ethical and psychological dilemmas about genetic testing, since still 
more has to be discovered related to this devastating disease.
Introduction
8Amyotrophic Lateral Sclerosis
Amyotrophic Lateral Sclerosis (ALS) is a human adult‑onset neurodegenerative 
disease, characterized by progressive weakness, muscle atrophy, spasticity, paralysis, 
and death, generally within 3 to 5 years after onset of symptoms. The symptoms are 
related to degeneration and loss of upper motor neurons in the cerebral cortex and 
lower motor neurons in the brain stem and spinal cord (1).
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percent of cases of ALS are familial; the others are
believed to be sporadic. In 1993, Rosen et al.
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 de-
scribed mutations in the gene encoding superoxide
dismutase 1 (SOD1) that account for 20 percent of
cases of familial ALS. The remaining 80 percent are
caused by mutations in other genes. Five percent of
people with apparently sporadic ALS also have 
 
SOD1
 
mutations. More than 90 
 
SOD1
 
 mutations involve
40 of the 153 amino acid residues. All 
 
SOD1
 
 muta-
tions are dominant, except for the substitution of ala-
nine for aspartate at position 90 (D90A), which can
be either recessive
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 or dominant.
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 The substitution
of valine for alanine at position 4 (A4V) is the most
common 
 
SOD1
 
 mutation.
Different 
 
SOD1
 
 mutations cause distinct syn-
dromes
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 that differ with respect to penetrance (pen-
etrance is usually 100 percent but is sometimes less),
SOD1 activity of erythrocytes (activity is usually nor-
mal but is sometimes depressed), age at onset (onset
is usually after the age of 40 but sometimes occurs
at a younger age), survival (survival ranges from 1 to
20 years), and clinical manifestations (the initial symp-
toms may be spinal or bulbar in nature). The histo-
pathological findings also vary. In patients with the
A4V mutation in 
 
SOD1, 
 
the corticospinal tracts are
largely spared.
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 Neuronal inclusions are not always
present; for example, they may be present in some
family members and absent in others.
Another autosomal dominant form of ALS pro-
gresses slowly and begins before the age of 25 years
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;
the gene has been mapped to chromosome 9q34.
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The gene for ALS with frontotemporal dementia has
 
Figure 1.
 
 Motor Neurons Selectively Affected in ALS.
Degeneration of motor neurons in the motor cortex leads to clinically apparent signs of upper motor neuron abnormalities: over-
active tendon reflexes, Hoffmann signs, Babinski signs, and clonus. Degeneration of motor neurons in the brain stem and spinal
cord causes muscle atrophy, weakness, and fasciculation.
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Figure 1. Motor neurons selectively affected in ALS patients
The French neurologist Jean‑Martin Charcot described for the first time ALS in 1874. 
In the United States it is known as Lou Gehrig disease, by the name of the famous 
baseball player who, in 1930, was the first confirmed victim of this disease. ALS cases 
represent about 85‑90% of motor neurons disease (MND), a heterogeneous group of 
adult‑onset neurodegenerative disease.
The term “amyotrophic” refers to the atrophy of muscle fibres, which leads to weakness 
of affected muscles and visible fasciculations that signify disease of the lower motor 
9neurons. “Lateral sclerosis” refers to the hardness to palpation of the lateral columns 
of the spinal cord in autopsy specimens, where gliosis follows degeneration of the 
corticospinal tracts. The clinical results are upper motor neuron signs: overactive 
tendon reflexes, Hoffmann signs, clonus, and Babinski signs. ALS refers to one 
specific form of motor neuron disease in which there are both upper and lower motor 
neuron signs (1).
Recently, population‑based studies have established that the incidence of ALS in 
Europe is fairly uniform at 2.16 per 100,000 persons/year. The mean age of onset 
for ALS varies between 55 and 65 years (2,3). Few ALS patients have an early onset 
that causes a different progression of the disease; patients with age at onset below 
41 years have survival 3 times longer than patients with an age at onset above 
60 years (4).
Men have a higher incidence of disease (3.0 per 100,000 persons/year) than do 
women (2.4 per 100,000 persons/year), although the incidence in men and women 
is about the same in familial disease (5). Explanations for this male excess have been 
attributed to possible protective hormonal factors in women, increased likelihood 
of males being exposed to such putative risk factors as trauma, physical activity 
and employment status (6). After menopause the ratio M/F is around 1, suggesting a 
neuroprotective effect of estrogens (7,8). Conversely, pregnancy seems to cause a fast 
progression of the disease (9).
Most ALS cases have no obvious family history and are referred to as sporadic ALS 
(SALS) whereas approximately 5‑10% of ALS patients have a family history, with a 
Mendelian pattern of inheritance (FALS). There is also a juvenile form of disease with 
age at onset before 25 years (jALS) (10). Familial ALS cases are indistinguishable from 
SALS on the basis of clinical and pathological criteria, which are very similar even if 
ALS patients show some degree of heterogeneity as far as symptoms, age of onset 
and disease duration. The mean age of onset for SALS is of about 60 year (2,3). Only 
5% of cases have an onset before the age of 30 years (3), although juvenile sporadic 
onset cases are being increasingly recognized (11). The age of onset of FALS is about 
a decade earlier than for sporadic cases. This form affects males and females equally; 
patients have a shorter survival than with ALS (12). Age of onset in FALS has a normal 
Gaussian distribution, whereas SALS has an age‑dependent incidence.
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On the basis of the clinical pattern in the initial phase of illness, different variants 
have been described, including bulbar, spinal and pseudoneuritic forms, flail arm 
syndrome, and Mill’s hemiparetic type. Bulbar‑onset ALS is more frequent in females 
and in older age groups, with tare 43% of patients over the age of 70 presenting with 
bulbar symptoms in comparison with 15% below the age of 30 (13). There is a general 
consensus in considering older age and bulbar‑onset as major negative prognostic 
factors (14). The upper motor neuron phenotype appears to be a strong independent 
predictor of long survival (15). Disease duration depends on the timing of involvement of 
respiratory muscles. Respiratory weakness may represent the onset symptom in 5% of 
patients or can take place later in the course of the disease, as in flail arm ALS and in 
upper motor neuron disease forms (15,16).
The overall median survival of patients with ALS mainly depends on site of onset 
of symptoms: 2‑3 years for bulbar‑onset cases and 3‑5 years for limb onset ALS 
cases (17,18). Large clinic cohort studies have shown 3 year and 5 year survival groups 
to be around 48% and 24% respectively, with approximately 4% surviving longer than 
10 years (19), whereas 5 year survival reported in population based studies is much 
lower and ranges from 4 to 30% (17).
Despite many clinical trials and various advances in the understanding of ALS, there 
has been little success in the search for disease modifying or neuroprotective agents. 
Riluzole is the only approved drug that has been shown to have a modest effect on 
prolonging life in ALS patients (13). The mechanism of action of riluzole is not entirely 
understood but is thought to include interference with N‑Methyl‑D‑Aspartate (NMDA) 
receptor mediated responses, stabilization of the inactivated state of voltage dependent 
sodium channels, inhibition of glutamate release from pre‑synaptic terminals, and 
increase of extracellular glutamate uptake (20).
Over 100 other neuroprotective agents have been studied in animal models and 
humans. Some agents that have been evaluated in phase II or III human clinical trials 
have shown inconclusive evidence or failed to demonstrate effectiveness for routine 
clinical practice.
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Epidemiology
Very recently in literature many epidemiological studies have appeared about the 
distribution of ALS according to sex, age and geographical origin. Through these 
studies it was possible to classify ALS in 3 categories:
• Sporadic ALS (SALS)
• Familial ALS (FALS)
• Western Pacific ALS 
Sporadic ALS
The incidence of SALS in the 1990’s is reported to be between 1.5 and 2.7 per 
100,000 persons/year (average 1.89) in Europe and North America, with a uniform 
incidence across these countries. The point prevalence in Western countries in the 
1990’s ranges from 2.7 to 7.4 per 100,000 (average 5.2). Furthermore the mortality 
rates of ALS in the 1990’s range from 1.54 to 2.55 per 100,000/year (7). Recently the 
annual incidence of the disease in Northern Italy, which has been reported as 2.64 per 
100,000 persons/year (men, 2.97/100,000; women, 2.32/100,000), seems to be 
remarkably similar to the ALS distribution in all Western countries (21).
Fifteen epidemiological studies have been performed by Worm in 2001 in order to 
provide accurate data on the frequency of ALS in Europe and in North America. 
These studies have pointed out a globally and steady increase of incidence (46%) 
and mortality rates (57%) in the 1990s as compared to the 1960s‑1970s period. 
This increase appears mainly due to Southern Europe countries, to female gender 
and to patients aged 75 years and over. These increases might be, at least in part, 
due to increased life expectancy in the last 40 years, to a better diagnosis since the 
appearance of the El Escorial criteria in the early 1990s and to a higher accuracy 
of death certificates collection. However this analysis doesn’t allow ruling out the 
hypothesis of a true increase in the incidence of motor neuron disease, possibly related 
to other impacting factors, such environmental ones (7).
In recent years many epidemiological studies have attempted to identify environmental 
factors associated with SALS. The endemic occurrence of ALS in regions such as in 
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the high‑risk areas of the Pacific cannot be fully explained by genetic factors and is 
stirring an animated discussion on gene‑environment interactions. Attention is focused 
in particular on the fruits of the locally growing cycad palms; indeed, geographic 
incidence rates for ALS are strongly correlated with concentrations of cycasin in 
traditional food prepared from the toxic seed of the cycad plant (22). Other putative 
environmental risk factors for ALS include pesticides and insecticides (23), and 
neurotoxins to which Gulf War veterans had an extended exposure (24).
Chiò et al. suggested that a factor related to professional football in Italy, or more 
factors acting together, such as heavy physical exercise, traumas or micro‑traumas, 
have a role in determining an increased risk of ALS. ALS might be related to either the 
use of illegal, toxic substances assumed to improve athletic performances or to the 
use of therapeutic drugs in excess of recommended doses or for a long period. Finally 
ALS might be related to environmental toxins such as fertilizers or herbicides used on 
football fields (25).
A number of epidemiological studies have assessed the association of cigarette 
smoking with ALS incidence. Compared with never‑smokers, the rate ratio (RR) of ALS 
for ever‑smokers was 1.04 (0.80‑1.34). The corresponding RR was 1.53 (1.04‑2.23) 
in women and 0.75 (0.53‑1.06) in men. Old age and female sex were associated 
with lower survival. Smoking was a predictor of mortality only in women. Comparing 
ever‑ versus never‑smokers, RR of death was 1.31 (1.04‑1.65) in women, and 0.90 
(0.72‑1.11) in men. In conclusion, smoking is associated with higher risk of ALS and 
worse survival in women but not in men (26).
The prevalence of ALS is estimated at 4‑6/100,000 persons with a uniform distribution 
across the world. Four well‑studied geographic areas with a high prevalence of ALS 
(clusters) are known: the Guam island in Micronesia, the Japanese Kii peninsula, 
the Western coast of former West Papua New Guinea, and an isolated tribe at Anguru 
on Groote Eylandt in the Gulf of Carpentaria (North Australia). In the Western Pacific 
form of ALS the prevalence is 50‑100 times higher than elsewhere in the world. 
There is a latitude‑related increase in ALS, with geographic age‑adjusted incidence 
rates ranging from 2.0 in Israel (32° latitude) to 8.0 in the Northern Scandinavian 
countries (>60° latitude) (22).
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The incidence of ALS varies with age and can be expressed as age‑specific incidence 
(21,27,28); about 80% of ALS cases are aged between 40 and 80 years, while 20% 
is outside this age range (29). ALS affects people of all ages but the age‑adjusted 
incidence rate varies greatly in different age groups. Incidence is very low in the first 
four decades (1.5/100,000/year), increases abruptly around age 40, reaching its peak 
between ages 60 and 79 (10‑15/100,000/year), and decreases thereafter (30).
This phenomenon may be due to the fact that in elderly patients ALS’s symptoms 
could be both confused with signs of aging and be masked by other diseases, such 
as cerebrovascular or radicular pain, nerve or muscle. Conversely, the presence of a 
peak in the age‑specific incidence curve suggests that the disease results from a time 
dependent exposure to some genetic or environmental risk factors. According to this 
hypothesis, early onset of the disease might reflect a harsher exposure to one or more 
of these risk factors (31).
In all these studies except one, the age‑specific incidence was greater for men than for 
women at all ages. However, as already mentioned, the male/female ratio for incidence 
(male to female ratio of around 1.5:1) was greater at younger ages. The data indicate 
a greater prevalence of spinal‑onset disease in men and a greater prevalence of 
bulbar‑onset disease in women. It is unclear why there should be differences in the site 
of onset between men and women, but it could be related to gender differences in the 
motor neurons in different regions (32).
There have been attempts to explain the different vulnerabilities of motor neurons in 
ALS. The vulnerability of bulbar motor neurons is related in part to the expression 
of N‑Methyl‑D‑Aspartate (NMDA) receptor subunits (33). Estrogen enhances NMDA 
receptor expression (34), so this mechanism may explain in part the phenomenon.
Males and females also differ in the proliferative ability of oligodendrocytes in 
the central nervous system (35). Furthermore, males have a shorter life span than 
females (36), and the loss of volume in the brain with aging occurs to a greater extent in 
men than in women (37). This difference in the ability to repair damage could be relevant 
to possible differences in the clinical course of ALS.
Average survival in ALS is widely quoted as 3‑5 years. Bulbar‑onset of symptoms, 
older age at onset and more definite El Escorial category at presentation have been 
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associated with reduced survival (19). Patients with bulbar‑onset disease are significantly 
older than those with spinal‑onset, thus the negative prognostic effect of bulbar‑onset 
is entirely covered by the older onset age of disease in these patients. Conversely Chiò 
et al. found that age and bulbar involvement were independently related to survival, 
which indicates that the faster progression in bulbar cases is not entirely due to older 
age at onset (38).
Although ventilation support can ease problems with breathing and prolong survival, 
it does not affect the progression of ALS; a non‑invasive assisted ventilation prolongs 
survival and improves or maintains quality of life in people with normal to moderately 
impaired bulbar function (39).
However, about 10 percent of patients survive for 10 or more years. These patients 
usually have phenotypic variants from “classic” ALS, such as the upper motor 
neuron only presentation of primary lateral sclerosis, which are associated with 
better prognosis (18).
Familial ALS
The familial form of ALS includes families in which at least two cases are observed 
in relatives separated by no more than four generations. The first case of FALS was 
reported by Aran in 1850, when he described 4 patients affected by progressive 
muscular atrophy within the same family.
In retrospective epidemiological studies carried out between 1958 and 1996, 0.8‑13.5% 
of patients with ALS reported family history. The frequency of FALS is strongly variable 
both in different geographical areas and within the same country.
Differences in these studies could be explained through several factors:
• inhomogeneous diagnostic criteria between different studies;
•  inadequate recording of pertinent family history in the patients’ charts;
• genealogical investigations not performed;
• different subtypes of ALS in different family members and disease not 
recognized as one;
• reluctance of the patient to report a hereditary disease;
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• loss of contact between different members of a family;
• early death to other causes of individuals in the family who transmit 
the gene defect;
• age of onset younger in the patients of successive generations, so that 
the offspring develops ALS before the parent who transmitted the gene 
defect (anticipation);
• incomplete disease penetrance;
• misdiagnosis of family members with ALS;
• illegitimacy.
Although most cases of ALS are sporadic, about 5‑10% of cases have a family history 
of ALS. While most cases of familial ALS are indistinguishable from sporadic disease, 
others have unique phenotypes (40). Comparative studies demonstrated some features 
as specific to FALS in comparison with SALS (41):
• age of onset is about a decade earlier than for sporadic cases;
• age of onset has a normal Gaussian distribution, whereas SALS has an 
age‑dependent incidence;
• men and women are affected equally;
• generally the disease has a longer duration;
• onset often occurs in the lumbosacral segment;
• sensitive symptoms are more frequent at the onset;
• degeneration of the posterior columns of the spinal cord, spino‑cerebellar traits 
and dorsal nucleus of Clarke is evident in 70% of patients with familial ALS.
The age of onset of familial ALS is normally distributed with a mean of 46 years.
Survival curves for familial ALS data also demonstrate a skewed distribution with 
a median survival time of 24 months, with 74% surviving at 1 year, 48% at 2 years 
and 23% at 5 years (42).
The phenotypic heterogeneity seen in sporadic forms of ALS are also common within 
families: for example, within a family age of onset may vary (over 30 years) as much 
duration of illness (0.5 to 5 years) and signs at onset (43). At its onset the disease is 
usually focal and asymmetrical (e.g. wasting of muscles of one hand), then it spreads 
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in a contiguous way. In most cases lower motor neuron involvement is conspicuous 
whereas involvement of upper motor neurons is less evident. The disease may 
present at first as a predominantly lower motor neuron form (progressive muscular 
atrophy), as a predominantly upper motor neuron form (primary lateral sclerosis), or as 
predominantly affecting bulbar muscles (progressive bulbar palsy) (42). Alternatively it 
may develop as classical ALS.
Based on a clinical, pathological, and genetic study of 14 families (44), at least three 
types of familial motor neuron disease can be distinguished (Table 1):
Type I
It is characterized by rapid, progressive loss of motor function with predominantly lower 
motor neuron manifestations and a course lasting less than 5 years. Pathological changes 
are limited to the anterior horn cells and pyramidal tracts.
Type II It is clinically identical to the first, but at autopsy additional changes are found in the posterior columns, Clarke’s column, and spino‑cerebellar tracts.
Type III It is characterized by a much longer survival, usually beyond 10 and up to more than 20 years in affected family members, but is otherwise similar to type II.
Table 1. Subclassification of FALS forms on a clinical basis
Western Pacific ALS
As already mentioned, four geographic areas in the Western Pacific with a high 
prevalence of ALS are known: the Guam island and Rota in Micronesia (Mariana 
island), the Japanese Kii peninsula, the Western coast of former West Papua New 
Guinea and an isolated tribe at Anguru on Groote Eylandt in the Gulf of Carpentaria 
(North Australia).
Immediately after World War II, an unusual frequency of ALS was noted in Guam. 
Epidemiological studies indicated that the prevalence of ALS in Guam was 50‑100 
times the prevalence anywhere else. In 1960s incidence was about 179/100,000 for 
men and 60/100,000 for women.
The Chamorros of Guam call the disease lytico‑bodig, and neuroscientists refer to it as 
the amyotrophic lateral sclerosis/Parkinsonism‑dementia complex (ALS‑PDC), because 
affected subjects are prone to manifest atypical Parkinsonism, dementia, motor neuron 
disease, or a combination of these three phenotypes.
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Several theories have been proposed to explain the high prevalence of ALS/PDC 
among the Chamorro population (45,46). Initially ALS and PDC were thought to represent 
genetic disorders (47). These early studies demonstrated that close relatives of affected 
subjects were at greater risk for disease than relatives of controls. In addition, there 
were many families with multiple individuals in two or more generations, including 
some pedigrees in which four successive generations were affected. Furthermore, 
the identification the ALS and PDC among Filipino migrants to Guam implicated 
environmental factors in the pathogenesis of these disorders. The cause of ALS/PDC is 
unknown; therefore, it is not known if its environmental aetiology is connected to single 
events or repeated and cumulative. The age of exposure and latency is also unknown 
but it is known that the annual incidence of ALS and PDC has steadily declined since 
1955 (48), and this finding must indicate that its cause ended many decades ago. 
The author does not know of any pathologically verified case born after 1951.
However, mathematical models constructed from over 2000 affected and non‑affected 
residents of Guam rejected purely environmental, autosomal dominant, and autosomal 
recessive hypotheses of disease transmission and may indicate that both genetic 
predisposition and environmental exposure are necessary to develop this condition (49).
Two types of environmental hypotheses have been proposed to account for Western 
Pacific ALS/PDC. One is the absence of essential minerals and the other is the 
presence of exogenous toxin common to affected areas. The possibility that neurotoxic 
trace elements might be related to ALS/PDC was first proposed by Yase in 1972 (50). 
Relatively high levels of aluminium and manganese and low levels of calcium and 
magnesium were found in samples of drinking water and soil in all three foci of  
ALS/PDC, including Guam, the Kii peninsula and Western New Guinea. Garruto 
et al. (51) have demonstrated deposition of aluminium in affected neurons, and in 
1989 have shown that the deficiency of calcium and magnesium in the soil leads 
to increased uptake of aluminium as an alternative source of cations, which is 
the possible cause of neuronal degeneration and death (52,53). Alternatively, the 
accumulation of iron with aluminium in neurons causes oxidative stress leading to 
degeneration of vulnerable neurons. The incidence of Guamanian ALS/PDC has been 
associated with prolonged exposure to an environment severely deficient in Ca2+ 
and Mg2+ (54).
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The leading candidate as the source of an exogenous toxin used to be the toxic seed 
of the false sago palm, Cycas circinalis (55). Cycad, used as food source in flour as well 
as poultice in traditional medicine by the Chamorros of Guam, is highly hepatotoxic if 
ingested in its raw form. However, the seeds are detoxified, through ritualistic washing, 
before use.
In the late 1980s Spencer et al. described neurological symptoms in cynomolgus 
monkeys that were fed large doses of beta‑methyl‑amino‑L‑alanine (BMAA) (56), an 
“unusual“ amino acid that is present in low quantities in cycad seeds. However, the 
doses required to achieve toxicity were unrealistic, and BMAA is readily removed 
from the seed with washing. However, Cox and Sacks have once more resurrected 
the cycad toxic theory by arguing for “biomagnifications” (or concentration) of toxins 
by consumptions of flying fox (Pteopus ariannusmariannus). The Chamarro people 
traditionally feasted on flying foxes, which consume large quantities of cycads (57). 
Very recently the neurotoxic effects of cholesterol β‑d‑glucoside (CG) and cycad 
phytosteryl glucosides have been associated with increased oxidative damage 
of neurons (58).
Chen and colleagues reported the disappearance of amyotrophic lateral sclerosis 
(ALS) from Guam over the past 30 years, when one third of the Island land was used 
for construction of huge military bases, which coincided with rapid changes in ecology 
and socio economy, and with Westernisation of the life style. This slow but steady 
decline is believed to be the consequences of radical changes from food collection 
to wage‑based life style and dietary improvement in recent years and removal of 
exogenous factors (59).
Clinical features
ALS may be suspected whenever an individual develops unexpected loss of function, 
or gradual, slowly progressive, painless weakness in one or more regions of the body, 
without changes in the ability to feel, and no other cause is immediately evident.
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The clinical diagnosis of ALS in a person requires the presence of both upper and 
lower motor neuron features and progression of disease. Typical ALS patients 
show symptoms related to focal muscle weakness. In lower motor neuron (LMN) 
involvement, fasciculations (involuntary muscle twitching, especially in tongue 
and limbs) may occur early on in the disease. In addition, typical signs of LMN are 
atrophy, muscular hypotonia and cramps. Patients with upper motor neuron (UMN) 
involvement generally are hyperreflexic and stiff. Reflexes may be diminished due to 
LMN involvement. UMN symptoms may include spasms and sudden, uncontrolled 
straightening movements of the lower limbs (spasticity). Babinski’s (anomaly of 
the cutaneous plantar reflex) and Hoffman’s (same for the upper limbs) signs are 
variably present in the early stage of disease. These symptomatic signs reflect 
degeneration and death of upper and lower motor neurons in the brain and spinal 
cord. The degeneration of at least 30% of small interneurons in the motor cortex and 
spinal cord also occurs, sparing however muscles that control eye movements and 
urinary sphincters (40).
The disease can be subdivided into bulbar‑ and spinal‑onset forms. Approximately 
75‑80% of patients with typical ALS have a spinal form of the disease (classical 
‘Charcot ALS’). They present with symptoms related to focal muscle weakness where 
the symptoms may start either distally or proximally in the upper limbs and lower limbs. 
Patients with upper limb onset have twice the likelihood for onset in the dominant arm, 
compared with the non‑dominant arm. There is equal likelihood for presentation in 
either lower extremity. Persons with upper limb onset may experience reduced finger 
dexterity, cramping, stiffness, and weakness or wasting of intrinsic hand muscles. 
This may lead to difficulty with actions such as buttoning clothes, picking up small 
objects, or turning a key.
Patients who have lower limb onset initially may complain of tripping, stumbling, 
or awkwardness when running. Foot drop is common, and patients may report a 
“slapping” gait. Focal muscle atrophy especially involves the muscles of hands, 
forearms or shoulders in the upper limbs, and proximal thigh or distal foot muscles 
in the lower limbs. Tendon reflexes are pathologically brisk in a symmetrical manner, 
including finger jerks in the upper limbs and positive crossed adductor reflex in the 
lower limbs. Abnormal spread of tendon reflexes beyond the stimulated muscle group 
may be evident. The Hoffmann’s and Babinski’s signs may be positive (13).
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Rarely, patients may notice focal muscle wasting before onset of weakness, 
and some patients may present with a spastic paraparesis. Patients may have noticed 
fasciculations or cramps preceding the onset of weakness or wasting for some months 
(or years), but rarely these are the presenting symptoms. The weakness is usually 
of insidious onset, and patients may notice that symptoms are exacerbated by cold 
weather. Although the disease is usually asymmetrical at onset, sooner or later the 
other limbs develop weakness and wasting, and most patients with time develop bulbar 
symptoms and eventually respiratory symptoms (although not necessarily in that 
sequence). Gradually, spasticity may develop in the weakened atrophic limbs, affecting 
manual dexterity and gait. During late stages of the disease patients may develop 
‘flexor spasms’, which are involuntary spasms occurring due to excess activation of 
the flexor arc in a spastic limb. Occasionally encountered symptoms include bladder 
dysfunction (such as urgency of micturition), sensory symptoms, cognitive symptoms 
and multi‑system involvement (e.g. dementia, Parkinsonism).
The bulbar‑onset form accounts for about 25% of ALS cases (12). Patients with 
bulbar‑onset ALS usually present dysarthria or, rarely, dysphagia for solid or liquids, 
up to the complete loss of verbal communication (anarthria) and fasciculations in the 
tongue. Limbs symptoms can develop almost simultaneously with bulbar symptoms 
and in the vast majority of cases will occur within 1‑2 years. Almost all patients with 
bulbar symptoms develop sialorrhea (excessive drooling) due to difficulty in swallowing 
saliva and mild UMN type bilateral facial weakness that affects the lower part of the 
face. “Pseudobulbar” symptoms such as emotional instability and excessive yawning 
are seen in a significant number of cases. Denervation of the respiratory muscles and 
diaphragm is generally the fatal event and, in most cases, it occurs within 5 years 
of disease onset. Patients with ALS may exhibit a range of cognitive abnormalities, 
ranging from impaired frontal executive dysfunction, in 20‑40% of patients, to 
FrontoTemporal Lobar Dementia (FTLD), in approximately 5% of cases (13).
About 5% of cases with ALS present with respiratory weakness without significant 
limb or bulbar symptoms. These patients present with two types of symptoms: 
respiratory failure or nocturnal hypoventilation such as dyspnea, orthopnea, disturbed 
sleep, morning headaches, excessive day time somnolence, anorexia, decreased 
concentration and irritability or mood changes (60,61). Thus, ALS is now regarded as a 
multi‑system degenerative disease, in which the earliest and most severe degenerative 
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changes tend to affect lower and usually upper motor neurons. Even within motor 
neuron groups, there is selective vulnerability. Certain groups of motor neurons, 
including those controlling eye movements and those in Onuf’s nucleus in the sacral 
spinal cord controlling the pelvic floor muscles, tend to be spared in ALS in comparison 
with other groups of motor neurons (62).
In the human motor neurons uptake of calcium via glutamate receptor ion channels 
represents one of the key processes for triggering second messengers as well as for 
mediating toxic events. Indeed, sustained elevation of intracellular calcium can result 
in activation of a cascade of damaging biochemical events. These calcium‑activated 
biochemical processes can injure neurons both directly and through the generation of 
free radicals (63).
The AMPA subtype of glutamate receptor is responsible for much of the fast excitatory 
transmission in mammalian CNS (central nervous system). In particular, the GluR2 
subunit of this receptor renders the AMPA receptor impermeable to calcium, thus the 
low expression of GluR2 by human motor neurons implies that most of the surface 
AMPA receptors expressed by this cell group are likely to be atypical and calcium 
permeable. This feature suggests that human motor neurons may differ from many 
other groups of neurons in the human CNS in expressing a high proportion of calcium 
permeable AMPA receptors (Figure 2) (62). 
Moreover less vulnerable motor neuron 
groups express parvalbumin and 
calbindin respectively (64). These proteins 
buffer intracellular calcium and play an 
important role in protecting neurons from 
calcium‑mediated injury following 
activation of glutamate receptors (65). 
Conversely, human motor neurons that 
are vulnerable in ALS do not express 
calcium binding proteins. Thus, the combination of the low expression of the GluR2 
AMPA receptor subunit and the absence of calcium buffering proteins may result in 
ALS susceptibility of motor neurons.
BA
Figure 2. Immunohistochemistry using an 
antibody that specifically detects the GluR2 
AMPA receptor subunit. A. Upper motor neurons 
(Betz cells) show no staining. B. Many other 
neuronal groups stain strongly. 
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Irrespective of the age at onset or of the presentation of the disease, ALS has always 
a progressive and invariably fatal course. Paralysis is progressive and leads to death 
within few years. Respiratory failure and other pulmonary complications or eventually 
insufficient caloric intake due to swallowing disorders (dysphagia) are the usual cause 
of death in ALS. However, patients who are kept alive by tracheostomy assisted 
ventilation are found to eventually develop a profound motor paralysis termed the 
‘totally locked‑in state’ (TLS), were there is paralysis of all voluntary muscles and 
varying degrees of oculomotor impairment (66).
The diagnosis of ALS is currently regulated according to the guidelines formulated 
in 1990 by the World Federation of Neurology. The El Escorial Criteria were initially 
developed to standardize the diagnosis and ensure inclusion of homogeneous patient 
population in clinical trials. The criteria were revisited in 1998 (Airlie House) and more 
recently in 2008 (Awaji‑shima) (Table 2):
The presence of
evidence of lower motor neuron degeneration by clinical, electrophysiological, 
or neuropathological examination
evidence of upper motor neuron degeneration by clinical examination
progression of the motor syndrome within a region or to other regions, as 
determined by history, physical examination, or electrophysiological test
The absence of
electrophysiological and pathological evidence of other disease processes that 
might explain the signs of lower or upper motor neuron degeneration
neuroimaging evidence of other disease processes that might explain the 
observed clinical and electrophysiological signs
Table 2. The revisited El Escorial criteria
Considering the four distinct body segments – bulbar, cervical, thoracic‑abdominal and 
lower back – it is possible to classify ALS in the following categories: 
El Escorial criteria (1994) (67)
• Definite ALS: upper and lower motor neuron signs in three regions.
• Probable ALS: upper and lower motor neuron signs in at least two regions with 
upper motor neuron signs rostral to lower motor neuron signs.
• Possible ALS: upper and lower motor neuron signs in one region, upper motor 
neuron signs alone in two or more regions, or lower motor neuron signs above 
upper motor neuron signs.
• Suspected ALS: lower motor neuron signs only in two or more regions.
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Airlie House (modified) criteria (2000) (68)
• Clinically definite ALS: clinical evidence alone of upper and lower motor neuron 
signs in three regions.
• Clinically probable ALS: clinical evidence alone of upper and lower motor 
neuron signs in at least two regions with some upper motor neuron signs rostral 
to (above) the lower motor neuron signs.
• Clinically probable‑laboratory‑supported ALS: clinical signs of upper and 
lower motor neuron dysfunction in only one region, or upper motor neuron signs 
alone in one region with lower motor neuron signs defined by electromyography 
criteria in at least two limbs, together with proper application of neuroimaging and 
clinical laboratory protocols to exclude other causes.
• Possible ALS: clinical signs of upper and lower motor neuron dysfunction in only 
one region, or upper motor neuron signs alone in two or more regions; or lower 
motor neuron signs rostral to upper motor neuron signs and impossibility to prove 
the diagnosis of clinically probable‑laboratory‑supported ALS.
• Suspected ALS: deleted category.
Awaji‑shima (modified) criteria (2008) (69)
• Definite ALS: defined by clinical or electrophysiological evidence by the 
presence of LMN as well as UMN signs in the bulbar region and at least two 
spinal regions or the presence of LMN and UMN signs in three spinal regions
• Probable ALS: defined on clinical or electrophysiological evidence by LMN and 
UMN signs in at least two regions with some UMN signs necessarily rostral to 
(above) the LMN signs
• Possible ALS: defined when clinical or electrophysiological signs of UMN and 
LMN dysfunction are found in only one region, or UMN signs are found alone in 
two or more regions, or LMN signs are found rostral to UMN signs; neuroimaging 
and clinical laboratory studies must have been performed and other diagnoses 
must have been excluded.
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ALS and other conditions
ALS has been generally considered a paradigm of pure motor neuron disorder. 
Nevertheless, it is currently recognized that pathological changes are not limited to the 
motor systems. Patients with ALS may exhibit cognitive abnormalities ranging from 
impaired frontal executive dysfunction to overt FrontoTemporal Dementia (FTD) (70). 
Very recently a study has shown that dementia occurs in approximately 14% of ALS 
patients and cognitive impairment, predominantly in the form of executive dysfunction, 
occurs in more than 40% of ALS patients (71).
FrontoTemporal Lobar Dementia (FTLD) affects 3‑4 individuals per 100,000 per year 
and is characterized by abnormalities of behaviour or language. The behavioural 
variant is denoted as FTD, and this is the second most common cause of dementia 
with onset under 60 years of age. Pathologically, FTLDs are classified according to the 
types of inclusions found in cortical neurons in post‑mortem examinations. In a large 
proportion of patients with FTLD, these inclusions contain TAR DNA‑binding protein 43 
(TDP‑43), which is similar to what is found in motor neurons of patients with ALS (72). 
Of the patients with FTLD, 15% also have ALS, but many more have some evidence of 
lower motor neuron involvement (73,74). This suggests that ALS and FTLD are two ends 
of the spectrum of one disease (Figure 3).
Confirming this clinical and pathological concept, ALS and FTD share many gene 
defects, including C9ORF72 (the chromosome 9 open reading frame 72), TARDBP, 
FUS (fused in sarcoma) and VCP (valosin containing protein) mutations (75,76).
ALS ALS‑Ci/Bi ALS‑FTLD FTLD‑MND FTLD
Figure 3. Spectrum of ALS‑FTLD
Patients for which there is clinical evidence for both disorders are said to have 
ALS‑FTLD. Many patients with ALS show some cognitive or behavioural changes but 
do not meet the criteria for FTLD: they are said to have ALS‑Ci/Bi (ALS with cognitive 
or behavioural impairment). Patients with FTLD can similarly show evidence of mild 
motor neuron involvement (clinically or on electromyographs) without developing ALS: 
they are said to have FTLD‑MND. Some patients have pure ALS or FTLD.
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Genetics aspects of ALS
The exact molecular pathway causing motor neuron degeneration in ALS is unknown, 
but is likely to be a complex interplay between multiple pathogenic cellular mechanisms 
which may not be mutually exclusive (77,78).
To date, 16 disease loci for ALS have been reported to be associated with typical 
ALS or atypical motor neuron disease, and 3 additional loci both with ALS and FTD, 
including loci and genes for ALS with juvenile onset (jALS), such as: alsin (ALS2) 
located on chromosome 2q33 and senataxin (ALS4) located on chromosome 
9q34 (Table 3).
Nomenclature Frequency Hereditarily Disease name Gene Locus Protein
ALS1 1‑4% SALS 20% FALS AD/AR SOD‑FALS SOD1 21q22.1
Cu‑Zn 
superoxide 
dismutase
ALS2 Rare AR Juvenile ALS type 3 ALS2 2p33 Alsin
ALS3 Single family AD FALS / 18q21 Unknown
ALS4 Rare AD
Distal 
hereditary 
neuropathy 
with signs 
pyramidal
SETX 9q34 Senataxin
ALS5 Rare AR Juvenile ALS SPG11 15q15.1‑q21.1 Spatacsin
ALS6 1% SALS 4% FALS AD/AR FALS FUS/TLS 16q12 FUS/TLS
ALS7 Single family AD FALS / 20ptel‑p13 Unknown
ALS8 Rare AD Proximal SMA VAPB 20q13 VAPB
ALS9 Rare AD? FALS ANG 14q11.2 Angiogenin
ALS10 2% SALS 5% FALS AD FALS
TARDBP 
(TDP‑43) 1p36
TAR DNA‑
binding protein
ALS11 Rare AD FALS FIG4 6q21 Phosphoinositide‑5‑phosphatase
ALS12 Rare AD/AR FALS OPTN 10p15‑p14 Optineurin
ALS13 ? AD FALS ATXN2 12q24 Ataxin 2
ALS14 0.5% SALS 1% FALS AD FALS VCP 9p13.3
Valosin 
containing 
protein
ALS15 0.5% FALS X‑linked FALS UBQLN2 Xp11.21 Ubiquilin 2
ALS16 ?% SALS 1‑2% FALS AD FALS PFN1 17p3.2 Profilin 1
ALS/FTD1 Rare AD ALS with FTD / 9q21‑q22 Unknown
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Nomenclature Frequency Hereditarily Disease name Gene Locus Protein
ALS/FTD2 5% SALS 35% FALS AD
ALS with mild 
cognitive 
impairment
C9ORF72 9q21.2‑9p13.3 C9ORF72
FTD‑ALS Rare AD
Complex 
disinhibition‑
dementia 
Parkinsonism‑
amyotrophy
MAPT 17q21.1 MAPT
FTD‑ALS
Rare ALS 
25% familial 
FTD
AD ALS with FTD, FTD GRN 17q21.31 Progranulin
FTD‑ALS Rare FTD, Rare ALS AD FTD and ALS CHM2B 3p11.2
Chromatin 
Modifying 
Protein 2B
Table 3. Causative genes of ALS and ALS‑FTD
Many disease loci could indicate a wide genetic and allelic heterogeneity of ALS. 
Therefore, ALS can be inherited in an autosomal dominant, autosomal recessive, 
or X‑linked manner. Variants of ALS have differing clinical presentation, rate of 
progression and prognosis; however, the age of onset seems to be independent of the 
type of disease transmission.
SOD1 (ALS1) is the first gene to be identified in autosomal dominant FALS pedigrees, 
which maps to chromosome 21q22.1. This gene encodes the antioxidant enzyme 
Copper Zinc (Cu‑Zn) Superoxide Dismutase. In literature mutations in SOD1 have 
been reported in ca. 20% of FALS and in ca. 1‑4% of SALS (40), even if in Italy a wide 
range of frequency is reported for SALS (ranging from 0% to 6.3%) (79). Recently, 
mutations in TARDBP gene (ALS10), encoding the TAR‑DNA binding protein TDP‑43 
and located on chromosome 1p36.22, have been linked to familial and sporadic ALS. 
Mutations of gene TARDBP were first reported in FALS cases in 2008; since then, 
mutations in this gene have been detected with an incidence of 4‑5% in FALS and 
up to 2% in SALS. A further ca. 4% of FALS cases and ca. 1% of SALS cases are 
associated to mutations in the fusion in malignant liposarcoma/traslocated in liposarcoma 
(FUS/TLS) gene (ALS6) (80). Other rare mutations have been described in Alsin (ALS2), 
Senataxin (SETX), Vesicle Associated Membrane Protein (VAMP), Angiogenin 
(ANG), Phosphoinositide‑5‑phosphatase (FIG4), Progranulin (GRN) and recently in 
Paroxonasis (PON) and Optineurin (OPTN).
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In addition there are several other genes potentially contributing to the development 
of ALS. In this broader complex genetic context, these genes are referred to as 
‘susceptibility genes’, as mutations in these genes may only lead to ALS in the 
presence of other genetic or environmental risk factors. The most important are: 
Neurofilament Heavy Subunit (NEFH), Apolipoprotein E4 (APOE), Glial Glutamate 
Transporter (EAAT2), Vascular Endothelial Growth Factor (VEGF). Finally other gene 
mutations have been identified in ALS cases, which may influence either survival or 
the progression of disease: Survival Motor Neuron (SMN), Cylial Neurotrophic Factor 
(CNFT) or Kinesin‑Associated Protein 3 (KIFAP3) (Table 4).
Gene Protein product Form of ALS Locus
NEFH Neurofilament heavy SALS/FALS 22q12.1‑q13.1 Susceptibility
PRPH Peripherin SALS/FALS 12q12‑q13
SMN Survival motor neuron SALS 5q12.2‑q13.3 Modifier
EAAT2 Glutamate transporter SALS/FALS 11p13‑p12 Susceptibility
GLUR2 Subunit of AMPA‑R SALS 4q32‑q33
CNTF Cylial neurotrophic factor FALS 11q12.2 Modifier
VEGF
Vascular 
endothelial growth 
factor
SALS/FALS 6p12 Susceptibility
APOE Apolipoprotein E SALS 19q13.2 Susceptibility
APEX1
Apurinic 
endonuclease 
DNA repair 
enzyme 1
SALS 14q11.2‑q12
HFE Haemochromatosis SALS 6p21.3 Susceptibility
KIFAP3 Kinesin‑associated protein 3 SALS/FALS 1q24.2 Modifier
PON Paroxonase SALS/FALS 7q21.2‑q22.1 Susceptibility
DCTN1 Dynactin 1 SALS/FALS 2p13 Modifier
Table 4. Susceptibility and modifier genes in ALS
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Molecular genetics diagnosis
The genetic/molecular diagnosis is carried out by amplification and direct sequencing 
of the causative genes of ALS and/or susceptibility genes.
Major genes analysed in this study are:
• SOD1, TARDBP, FUS and C9ORF72 in the familial and/or sporadic form 
of disease
• TARDBP, FUS and C9ORF72 for the ALS‑FTD forms of disease
• SETX in the juvenile form
C9ORF72 (ALS‑FTD2)
A large hexanucleotide (GGGGCC) repeat expansion in the first intron of C9ORF72 
located on chromosome 9p21 is the most common mutation detected in patients with 
familial ALS (75,76).
C9ORF72 contains a GGGGCC hexanucleotide (G4C2) sequence that is located 
between two transcription initiation sites (Figure 4). The GGGGCC hexanucleotide 
repeat is located between two non‑coding exons of C9ORF72, which encodes a 
completely uncharacterised protein with unknown function.
Exon 1a
(GGGGCC)n
Exon 1b Exon 2 Exon 3 Exon 4 Exon 5 Exon 6 Exon 7 Exon 8 Exon 9 Exon 10 Exon 11
Long transcript -> long isoform (481 aa)Short isoform (222 aa)Distal initiation site
Proximal initiation site
ATG
Figure 4. C9ORF72 contains 11 exons with ATG in the second one. It generates a long 
( exons 2 through 11) and short (exons 2 through 5) isoform
Two different isoforms of the protein are predicted to be generated from a total of three 
or more different C9ORF72 transcripts. In most normal individuals, the GGGGCC 
hexanucleotide is repeated two‑to‑five times. It is rarely repeated more than five times 
and is never repeated more than 30 times. Consequently, a cut‑off of 30 repeats 
is commonly used to differentiate between pathogenic and non pathogenic repeat 
sizes (76). However, the repeat size of 30 is also present in control subjects and 
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therefore this generates uncertainties in the attribution of pathological significance. 
For sure, fewer than 10 repeats are not associated with a pathological phenotype 
whereas the role of intermediate repeat sizes (11‑29) is not yet known. Conversely 
affected individuals with C9ORF72 mutations harbour expanded alleles with repeats 
reaching up to hundreds and thousands.
Unexpectedly, several groups show reduced levels of at least one C9ORF72 
transcript in expanded‑repeat carriers, suggesting a possible loss‑of‑function disease 
mechanism (81). The accumulation of transcripts containing the GGGGCC repeat as 
nuclear RNA foci in the frontal cortex and spinal cord of C9ORF72 mutation carriers, 
however, has also been demonstrated, favouring a toxic RNA gain‑of‑function disease 
mechanism in line with most other non‑coding expansion disorders (75).
An abnormal expansion of this sequence is found in about 40% of families with ALS 
and in about 7% of patients with supposed SALS (82). In FALS patients the mutation 
frequency varies between different populations, countries and regions, ranging from 
0% to 18% in Asiatic countries to 46% in Finland and France; the percentage of 
mutated cases raises to 50‑72% in families with ALS/FTD phenotype (83).
To date, less than a year after the discovery, more than 30 articles have described 
frequencies of C9ORF72 repeat expansions in ALS and FTD populations, across USA, 
Europe, Australia, and Asia. In Figure 5, Bitterswijk et al. have provided a graphic 
representation of these frequencies. This representation suggests that C9ORF72 
mutations account for 34.2% of the familial ALS cases, 5.9% of the sporadic ALS 
cases, 25.9% of the familial FTD cases, 5.1% of the sporadic FTD cases, and 0.17% 
of the controls. Hence, these frequencies underline that C9ORF72 repeat expansions 
are currently the major genetic cause of ALS and/or FTD worldwide (81,82,84).
At a neuropathological level, patients with mutations in C9ORF72 show 
TDP‑43‑immunoreactive protein aggregates, and presence of ubiquitin‑positive, 
TDP‑43‑negative inclusions in a variety of neuroanatomical regions (85). Comparing 
the phenotype with that of patients carrying mutations in other ALS‑related genes 
and of patients with unidentified genetic defects, those with C9ORF72 expansion 
consistently show some specificity. The most notable one is a significantly higher 
frequency of cognitive impairment, which affects 40‑50% of cases compared with 8‑9% 
of non‑C9ORF72 expansion cases. Moreover in patients carrying C9ORF72 mutations 
bulbar‑onset seems more frequent and median survival consistently lower than in 
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patients carrying TARDBP, SOD1 or unknown mutations. C9ORF72 expansion is more 
frequent among patients with onset >61 years (86).
The penetrance of the mutation is probably 50% around the age of 60 years and nearly 
100% above the age of 80 years (82). Many questions about the genotype‑phenotype 
correlation remain to be answered. One question concerns the intergenerational 
instability of the repeat. The age‑of‑onset has been reported to be 7 years younger 
in the subsequent generation, but this may reflect ascertainment bias (87). Another 
question concerns a possible effect of length of expansion and of homozygosity on 
disease severity, and the possibility that the normal allele influences the pathogenicity 
of the repeats (88).
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FIGURE 1. C9ORF72 mutation frequencies worldwide. Percentages reported in (a) familial amyotrophic lateral sclerosis (ALS)
patients, (b) familial frontotemporal dementia (FTD) patients, (c) sporadic ALS patients, and (d) sporadic FTD patients. Cohorts
of less than 10 individuals were not included. Only reported individuals with more than 29 repeat expansions were
considered to have a C9ORF72 mutation. In general, error bars represent 95% confidence intervals, as calculated with the
Wald method. If multiple studies were conducted for one country, then error bars represent standard errors. For these
countries, the average of all conducted studies was calculated, applying equal weight to all of them. The same method was
used to calculate an average for all reported countries in Europe, countries in North America, other countries (Other), and an
overall average (World). Graphpad Prism version 5.04 (http://www.graphpad.com) was used to perform these analyses.
When mutation frequencies of other genes were reported, they were incorporated, to give a better impression of the actual
mutation percentage in the general ALS/FTD population. If authors stated that the same (sub)group was used in multiple
studies, then this (sub)group was only included in one of the studies. Majounie et al. [47&&], Chio et al. [49&], and Renton
et al. [19&&], however, did include the same subset of 29 familial ALS samples without specification, and therefore, this
relatively small amount of samples could not be excluded. More details about the studies included in our comparison can be
found in Supplementary Table 1, http://links.lww.com/CONR/A18.
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Figure 5. C9ORF72 mutation frequencies worldwide
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SOD1 (Cu‑Zn Superoxide Dismutase)
The human SOD1 gene is located on chromosome 21q22.11, is composed of five 
exons and encodes for a 153 residues long protein. SOD1 is a 32 kDa homodimeric 
metalloenzyme, in which each monomer consists of an eight‑stranded beta‑barrel 
and binds a copper and a zinc ion. SOD1 is ubiquitously expressed, highly conserved 
and represents ca. 1% of all cytoplasmic proteins. This enzyme is highly expressed 
in nervous tissue, liver and erythrocytes. SOD1 catalyses the conversion of the 
superoxide radical anion (O2
.–) to molecular oxygen (O2) and hydrogen peroxide 
(H2O2) 
(89). Then it is reduced to water by glutathione peroxidase and catalase.
4 SOD
+ 4H +
+
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2
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GSH
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4  GSH
2GSSG
GSH
peroxidase
O2
2 orO2H2
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Figure 6. Function of SOD1
To date, more than 150 different SOD1 mutations have been reported  
(http://alsod.iop.kcl.ac.uk), the vast majority of which are missense substitutions 
distributed throughout the five exons of the gene, although a small percentage of 
nonsense mutations, insertions and deletions have also been described. Of these 
mutations, more than 100 are missense mutations in 66 codons leading to the 
exchange of one amino acid for another but retaining the full‑length polypeptide. 
About 10 mutations are nonsense mutations that alter the length of the final 
polypeptide. Most of these are in the 3’ end of exon 4 or in exon 5. The shortest 
polypeptide contains 121 amino acids and the longest 156 amino acids (90). 
Of particular interest is the discovery, in 2009, of an activated pseudo‑exon deep inside 
intron 4, which results in the addition of 7 novel amino acids after exon 4, followed by 
a stop codon (91).
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The mutations are scattered all over the molecule with preference for exons 4 and 5. 
Only few mutations have been found in the 24 codons of exon 3 that encode the amino 
acids forming the catalytic site and the zinc loop. Even more striking is the absence of 
mutations between Q22 and G37 in exons 1 and 2. The observations that no mutations 
have been found in these 14 codons, that all truncating mutations lie in exons 4 and 5, 
and that no null mutations have been found suggest that at least the amino terminus 
of the SOD1 polypeptide is essential for the cytotoxic effect (92). All of these mutations 
in SOD1 are associated with autosomal‑dominant FALS, except for two – D90A and 
D96N – which can cause both dominant and recessive ALS. The recessive inheritance 
of the D90A mutation has been reported mainly in Scandinavian families.
The majority of mutations in SOD1 are missense mutations and there is no clear 
correlation with the clinical expression of the disease (genotype‑phenotype correlation). 
This inter‑ and intra‑familial variability precludes precise predictions on the course of 
the disease. Clinical characteristics, age at onset, site of onset and survival vary greatly 
between and among specific mutations (22). A notable exception is represented by 
A4V, the mutation most frequently observed in ALS1 pedigrees, which is consistently 
associated with a high penetrance, younger age at onset, prevalence of lower motor 
neuron signs, and a very rapid disease course, usually less than 12 months (93).
Some other of the SOD1 mutations is often associated with ‘early onset’ (G37R, L38V), 
‘shorter survival’ (A4V) or relatively ‘benign’ forms of ALS (G37R, G41D, G93C, and 
H46R). However, these associations must be interpreted with caution when used to 
give a prognosis in individual cases (22). In Italy the following mutations have been 
described: A4V, G12R, G41S, V47F, L84F, G93D, A95T, I113T (94) and L144F (95).
In 2005 Battistini et al. (96) showed the results of a referred based multi‑centre study on 
the distribution of SOD1 gene mutations in the largest cohort of Italian ALS patients. 
Two hundred and sixty‑four patients (39 FALS and 225 SALS) of Italian origin were 
studied. In 7 out of 39 FALS patients the authors found an association between type of 
SOD1 gene mutations and phenotype. For example the G41S mutation was identified 
in four patients belonging to four unrelated families. The clinical phenotype of the four 
probands was quite uniform with early UMN and LMN involvement in one or both lower 
limbs, rapidly spreading to upper limbs, appearance of bulbar signs within 1 year, and 
death a few months later. The patient carrying the G12R mutation reported signs of 
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lower motor neuron involvement. The disease course was slowly progressive with 
bulbar symptoms developed in late stage and death after 7 years from disease onset. 
For the L144F mutation a great variability of age at onset and disease duration was 
observed among affected relatives, while clinical presentation, prominently affecting the 
lower limbs, was quite uniform (96).
The exact mechanism by which SOD1 mutations lead to ALS pathology is unknown 
although numerous hypotheses have been proposed to explain SOD1‑mediated 
toxicity, such as misfolded proteins aggregation, oxidative stress, mitochondrial 
dysfunction, endoplasmic reticulum stress, glutamate excitotoxicity, inflammation and 
microglial activation, and axonal transport abnormalities (80). Much information about the 
role of SOD1 in the pathogenesis of ALS comes from animal models and the SOD1G93A 
mice are the most commonly used models for ALS studies. SOD1 transgenic animal 
models recapitulate many of the features of ALS, including motor neuron degeneration, 
paralysis and premature death (97). Interestingly, SOD1 knock‑out mice do not develop 
ALS, which supports the notion that toxic gain of function may be responsible for the 
motor neuron degeneration in SOD1G93A mice since enzymatic activity is retained in 
SOD1G93A mutation (80). Most evidence indicates that FALS‑linked mutant SOD1 gain a 
toxic function, which may stem from mutant‑specific characteristics such as enhanced 
aggregation propensity, the formation of aberrant protein interactions, or intracellular 
mislocalisation. The accumulation of SOD1‑rich proteinaceous deposits in the spinal 
cord led to the hypothesis that SOD1 mutants are, or become, unstable and misfold 
to form high‑molecular‑weight aggregates that are selectively toxic to motor neurons. 
Immunohistochemical studies have localized these inclusions predominantly to motor 
neurons and, in some cases, astrocystes (Figure 7) (98). Other toxic effects of SOD1 
mutations may involve increased vulnerability to excitotoxic mechanisms by selective 
inactivation of the glutamate transporter, EAAT1, or by mitochondrial degeneration (22).
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Figure 7. A. An inclusion from the spinal cord of a FALS patient, expressing a SOD1 mutation 
(white arrowheads). B. SOD1 positive inclusions from the spinal cords of end‑stage transgenic 
mice (white arrowheads). C. Fibrillar nature of inclusions in mice. The letter “m” denotes 
mitochondria. D. Fibrillar aggregates in mice.
TARDBP (TAR‑DNA Binding Protein)
In 2006, the transactive response DNA binding protein 43 (TDP‑43) was recognized 
as a primary protein component of intracellular ubiquitinated inclusions in most cases 
of ALS and frontotemporal lobar degeneration with ubiquitin‑positive inclusions 
(FTLD‑U) (72). Now it is clear that inclusions are present in both sporadic and familial 
cases of ALS and FTLD‑U with or without MND.
Human TARDBP gene is located on chromosome 1p36.22 and encodes for the 
43KDa TAR DNA‑binding protein (TDP‑43). This protein is 414 amino acids long and 
is encoded by six exons. It contains two RNA‑recognition motifs (RRM1 and 2) and 
a C‑terminal glycine‑rich region that may mediate interactions with other proteins (99). 
TDP‑43 has a bipartite nuclear localization signal (NLS) between the N terminus 
and RRM1, and one nuclear export signal (NES) in RRM2. TDP‑43, belonging to 
ribonucleoprotein family, is predominantly nuclear, although the protein is synthesized 
in the cytoplasmic compartment and is capable of shuttling between nucleus and 
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cytoplasm. It is involved in a variety of functions in nucleus processes, including gene 
transcription, RNA splicing, microRNA processing and stabilization as well as transport 
of mRNA.
Almost all the TARDBP mutations identified in ALS patients are located in exon 6, 
which encodes the C terminal glycine‑rich part of the protein. Most are missense 
mutations, but there are a few deletion mutations that give rise to a protein 
truncated at the very C terminal (100). Although originally identified as binding to 
the polypyrimidine‑rich sequence of the transactive response element of the HIV 
virus, TDP‑43 has subsequently been shown to have roles in regulating alternative 
splicing of numerous genes including FUS, VCP, Progranulin, and other transcripts 
encoding neurodegenerative disease‑associated proteins as well as many other RNA 
processing genes (101).
Collectively, there are 70 distinct TARDBP point mutations or variants identified to 
date, including 28 of the above‑mentioned missense mutations, two benign missense 
mutations, one nonsense mutation, six synonymous mutations, seven mutations in the 
5’‑untranslated region (UTR), 21 intronic mutations, and five mutations in the 3’‑UTR 
region of TARDBP (102). These mutations all seem to show an autosomal dominant 
pattern of inheritance. The majority of these mutations occur in highly conserved amino 
acids lying in exon 6 of TARDBP, which encodes ca. 60% of the TDP‑43 protein and 
more than 70% of the entire mRNA transcript. In the light of these observations, it is 
clear that exon 6 and its encoded glycine‑rich domain are critical components of the 
TDP‑43 proteins (102).
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Amyotrophic lateral sclerosis (ALS) is an adult-onset neuro-
degenerative disorder in which premature loss of motor neu-
rons leads to fatal paralysis with a typical disease course of 
1 to 5 years. Most forms of ALS are spor dic, but ~10% of 
patients have an inherited familial form of the disease and 
a clear family history. Understanding of ALS pathogenesis 
began with the landmark discovery of dominant causative 
mutations in the gene encoding copper/zinc superoxide dis-
mutase 1 (SOD1) in ~20% of familial ALS cases and ~1% of 
sporadic cases. Subsequently, other even rarer familial cases 
with atypical disease features were linked to mutations in sev-
eral other genes.
Most efforts to understand ALS pathogenesis over the past 15 
years have focused on m ations in the ubiquitously expressed 
SOD1. No consensus has yet emerged as to how SOD1 muta-
tions lead to selective premature death of motor neurons, except 
that damage within motor neurons expressing mutant SOD1 
drives disease onset, whereas damage within their glial cell neigh-
bors expressing mutant SOD1 accelerates disease progression 
(Yamanaka et al., 2008). Multiple toxicity pathways have been 
implicated including the ability of misfolded mutant SOD1 to trig-
ger aberrant mitochondrial function, endoplasmic reticulum stress 
pathways, axonal transport defects, or excessive production of 
extracellular superoxide radicals. Views about ALS pathogenesis 
Rethinking ALS: The FUS about TDP-43
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Mutations in TDP-43, a DNA/RNA-binding protein, cause an inherited form of the neurodegenerative 
disease amyotrophic lateral sclerosis (ALS). Two recent studies (Kwiatkowski et al., 2009; Vance 
et al., 2009) now report that mutations in FUS/TLS, another DNA/RNA-binding protein, also trigger 
premature degeneration of motor neurons. TDP-43 and FUS/TLS have striking structural and func-
tional similarities, implicating alterations in RNA processing as a key event in ALS pathogenesis.
Figure 1. TDP-43 and FUS/TLS Mutations in ALS
(A) Thirty dominant mutations in TDP-43 have been identified in sporadic (red) and familial (black) ALS patients, with most lying in the C-terminal glycine-rich 
region of TDP-43. All are missense mutations, except for the truncating mutation TDP-43Y374X.
(B) Fourteen mutations in FUS/TLS have been identified in familial ALS cases, with most lying in the final 13 amino acids of this protein (R514S and G515S are found 
in cis). (Data compiled from Kwiatkowski et al., 2009; Vance et al., 2009; domains from http://www.uniprot.org and http://www.cbs.dtu.dk/services/NetNES.)
Figure 8. TDP‑43 gene structure
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It was suggested that specific mutations in TDP‑43 may alter the phosphorylation state 
of TDP‑43 or increase TDP‑43 aggregation. Thus, it is plausible that three missense 
mutations, i.e. S379C, S379P and S393L, are pathogenic because they abolish 
phosphorylation target sites for casein kinase I (103,104), thereby implying that reduced 
or impaired phosphorylation of TDP‑43 at these sites may play a mechanistic role in 
the onset or progression of ALS. Conversely, 9 other pathogenic missense mutations 
that replace glycine‑rich domain amino acids with serine or threonine would be 
predicted to increase the hyperphosphorylation state of TDP‑43 (103,105,106). Further, the 
Q331K and N345K mutations could be pathogenic as a result of creating novel targets 
for ubiquitination, whereas the G348C and S379C mutations may be predisposing 
to ALS by increasing the propensity for TDP‑43 to aggregate through disulfide 
bond formation (105).
The majority of ALS patients harbouring missense mutations in the TARDBP gene are 
characterized by a spinal‑onset of disease in both upper and lower motor neurons. 
Bulbar muscle symptoms are less frequent at the onset of the disease; however, 
several ALS patients who presented with upper and lower motor neuron involvement 
developed bulbar symptoms at follow up examination. Of note, a unique TARDBP 
missense mutation (Ala382Thr) has been found in approximately one third of all ALS 
cases in the Island of Sardinia, a genetic isolate phylogenetically distinct from other 
European populations (107).
Of the patients with ALS, 15% have FTD with TDP‑43‑positive inclusions in cortical 
neurons, whereas at least 50% have evidence for subtler cognitive and/or behavioural 
dysfunction (108). Some carriers of the TARDBP mutation presenting FTLD show 
evidence of mild motor neuron involvement without developing ALS (FTD‑MND). 
Therefore patient with TARDBP mutation develop typical ALS with some variability 
within families in the site and age of onset. Chiò et al. in 2010 identified 3 index cases 
of familial ALS carrying the p.Ala382Thr missense mutation of the TARDBP gene and 
with clinical, neuroimaging, and neuropsychological features of FTLD (109).
Corrado et al. had previously described the same mutation in one patient with ALS who 
displayed no apparent cognitive impairment (103). Finally, a TARDBP missense mutation 
has now been described in one patient with sporadic FTLD‑TDP, who presented with 
behavioural impairment but no clinical signs of MND (110,111).
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Since most TARDBP mutations are private (within a single family), it is difficult to 
establish clear genotype‑phenotype correlation. It has been suggested that A382T, 
which is the most commonly observed variant, may be associated with predominantly 
lower motor neuron disease, with an asymmetrical onset in the distal muscles of the 
limbs, subsequently spreading to proximal muscles and with relative sparing of the 
bulbar muscles (103). Moreover, the fact that the same genetic mutation can cause both 
ALS and FTLD‑TDP suggests that these two clinical entities might be considered as 
two ends of a spectrum of TDP‑43 proteinopathies.
FUS/TLS (Fusion in malignant liposarcoma/traslocated 
in liposarcoma)
The identification of TDP‑43 in ALS pathogenesis fuelled the discovery, recently 
reported by Kwiatkowski et al. and Vance et al. (112,113), of additional ALS mutations in 
a gene encoding another DNA/RNA‑binding protein called FUS/TLS. They identified 
novel variants in the FUS gene as the disease causing‑mutations in ALS families. 
Mutations in FUS gene are identified based on a linkage analysis in a large Cape 
Verde family with autosomal recessive ALS (112) and in numerous British kindreds with 
autosomal dominant ALS (113).
The locus for ALS6 has been mapped to region 16p11.2 containing the FUS gene. 
The FUS/TLS protein is 526 amino acids long and is encoded by 15 exons. It is 
characterized by an N‑terminal domain enriched in glutamine, glycine, serine, and 
tyrosine residues (QGSY region), a glycine‑rich region, an RNA‑recognition motif 
(RRM), multiple RGG repeats implicated in RNA binding, a C‑terminal zinc finger motif, 
and a highly conserved C‑terminal region (99).
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1 to 5 years. Most forms of ALS are sporadic, but ~10% of 
patients have an inherited familial form of the disease and 
a clear family history. Understanding of ALS pathogenesis 
began with the landmark discovery of dominant causative 
mutations in the gene encoding copper/zinc superoxide dis-
mutase 1 (SOD1) in ~20% of familial ALS cases and ~1% of 
sporadic cases. Subsequently, other even rarer familial cases 
with atypical disease features were linked to mutations in sev-
er l other genes.
Most efforts to understand ALS pathogenesis over the past 15 
years have focused on mutations in the ubiquitously expressed 
SOD1. No consensus has yet emerged as to how SOD1 muta-
tions lead to selective premature death of motor neurons, except 
that damage within motor neurons expressing mutant SOD1 
drives disease onset, whereas damage within their glial cell neigh-
bors expressing mutant SOD1 accelerates disease progression 
(Yamanaka et al., 2008). Multiple toxicity pathways have been 
implicated including the ability of misfolded mutant SOD1 to trig-
ger aberrant mitochondrial function, endoplasmic reticulum stress 
pathways, axonal transport defects, or excessive production of 
extracellular superoxide radicals. Views about ALS pathogenesis 
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Mutations in TDP-43, a DNA/RNA-binding protein, cause an inherited form of the neuro egenerative 
disease amyotrophic lateral sclerosis (ALS). Two recent studies (Kwiatkowski et al., 2009; Vance 
et al., 2009) now report that mutations in FUS/TLS, another DNA/RNA-binding protein, also trigger 
premature degeneration of motor neurons. TDP-43 and FUS/TLS have striking structural and func-
tional similarities, implicating alterations in RNA processing as a key event in ALS pathogenesis.
Figure 1. TDP-43 and FUS/TLS Mutations in ALS
(A) Thirty dominant mutations in TDP-43 have been identified in sporadic (red) and familial (black) ALS patients, with most lying in the C-terminal glycine-rich 
region of TDP-43. All are missense mutations, except for the truncating mutation TDP-43Y374X.
(B) Fourteen mutations in FUS/TLS have been identified in familial ALS cases, with most lying in the final 13 amino acids of this protein (R514S and G515S are found 
in cis). (Data compiled from Kwiatkowski et al., 2009; Vance et al., 2009; domains from http://www.uniprot.org and http://www.cbs.dtu.dk/services/NetNES.)
Figure 9. FUS/TLS gene structure
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The FUS protein resembles TDP‑43, and has been implicated in alternative splicing, 
genomic maintenance, and transcription factor regulation (114). Like TDP‑43, FUS/TLS 
is almost ubiquitously expressed. It is mainly localized in the nucleus, but cytoplasmic 
accumulation has been detected in most cell types.
Analysis of the brains and spinal cords of ALS patients with FUS/TLS mutations 
revealed normal staining of FUS/TLS in the nuclei of many neurons and glial cells 
but aggregates of FUS/TLS in neuron cytoplasm. Cytoplasmic inclusions containing 
the FUS/TLS protein are absent in normal individuals, in ALS patients with SOD1 
mutations, and in sporadic ALS patients who presumably are positive for TDP‑43 
aggregates. Importantly, TDP‑43‑positive inclusions are absent in ALS patients with 
FUS/TLS mutations, implying that neurodegenerative processes driven by FUS/TLS 
mutations are independent of TDP‑43 aggregation (99).
Mutations in FUS cause ALS and almost all are dominant, although the first one 
was identified in a Cape Verdian recessive pedigree (H517Q) (112). Up to now, more 
than 50 different mutations have been described, the vast majority of which are 
missense substitutions and the rest are frameshift or nonsense mutations. To date only 
2 insertion/deletion mutations in the G‑rich region of FUS have been described (112). 
Several missense mutations were revealed predominantly in exon 14 and 15, which 
encode the C‑terminus, the commonest being Arg521Cys (113). Forty‑two mutations 
in exons 3, 5, 6, 14 and 15 have now been reported. Although genotype‑phenotype 
correlations are not possible for the majority of FUS mutations, it has been suggested 
that mutations of arginine 521, in particular R521C, may result in an uncommon 
phenotype characterized by a symmetrical proximal spinal‑onset, with early 
involvement of the axial muscles (115).
FUS mutations have been found in patients with ALS who may or may not also have 
FTLD, but not unequivocally in patients with ‘pure’ FTLD (116). Van Langenhove et al. 
identified one patient with FTLD with a novel missense mutation, M254V, which was 
absent in 638 control individuals (117).
In the brain and spinal cord of patients with FUS mutations, FUS‑positive inclusions 
are present (112,113). The mutations in FUS gene P525L, c.1554−1557delACAG and, to 
a lesser degree, R495X are associated with an aggressive phenotype of ALS, which 
affects patients in the first or second decade of life and is fatal after 1‑2 years (118,119).
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Chiò in 2009 analysed 52 index cases from seven Italian regions with non‑SOD1 
and non‑TARDBP FALS to define the spectrum and frequency of FUS/TLS mutations 
in Italian population. He found two multi‑generational families carrying mutations in 
the FUS gene – one heterozygous missense mutation in a family of Northern Italian 
origin (R514S), and another heterozygous missense mutation in a family of Sicilian 
origin (P525L). The clinical phenotype was similar within each of the families, with a 
predominantly upper limb onset in the family carrying the p.R514S mutation (young 
mean age at onset and rapid progression) and bulbar‑onset, with very young age and a 
rapid course in the family carrying the p.P525L mutation, confirming that this particular 
FUS mutation results in a highly aggressive form of ALS (120).
SETX (Senataxin)
ALS4, initially mapped to chromosome 9q34, has subsequently been found to be 
caused by mutations in the SETX gene (121). The gene is composed of 26 exons and 
encodes for the 2.677‑residue long protein Senataxin.
Figure 10. Exon organization and protein of SETX respectively
The Senataxin protein shares extensive homologies with the fungal Sen1p proteins. 
Saccharomyces cerevisiae Sen1p is involved in splicing and termination of tRNA, small 
nuclear RNA and small nucleolar RNA and has RNA helicase activity encoded by its 
C‑terminal domain (122). The C terminus of Senataxin contains a classical seven‑motif 
domain found in the superfamily I of helicases, suggesting that it is a putative DNA/RNA 
helicase. The C‑terminal domain of Senataxin also shares extensive homology with 
RENT1/Upf1 and IGHMB2, two members of the superfamily I of helicases.
RENT1/Upf1 has been shown to be involved in nonsense‑mediated RNA decay and 
possesses both DNA and RNA helicase activity with a 5’‑3’ polarity of unwinding. 
IGHMB2, dysfunctional in spinal muscular atrophy (SMA) with respiratory distress, 
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has been described as a DNA binding protein with transcriptional transactivating 
properties (123).
Senataxin is a ubiquitously expressed DNA/RNA helicase, possibly involved in repairing 
DNA double‑strand breaks following oxidative stress (124). Moreover, it has been shown 
to bind RNA polymerase II and other proteins involved in mRNA transcription and 
processing, suggesting that it is involved in transcriptional regulation (123).
Interestingly, SETX mutations, mostly leading to a premature termination of the protein 
product, have been described in two different pathologies: ataxia‑ocular apraxia‑2 
(AOA2) with an autosomal recessive pattern of inheritance and juvenile ALS (jALS). 
This jALS is an autosomal dominant disorder characterized by a childhood‑ or 
adolescent‑onset and slow disease progression. Patients usually develop symmetrical 
weakness and atrophy of the distal muscles of the limbs in their second decade. 
The phenotype is characterized by the involvement of the corticospinal tracts 
(pyramidal signs associated with degeneration of motor neurons in the brain and spinal 
cord), while bulbar and respiratory muscles are consistently spared (125).
To date 3 different missense mutations (L389S, R2136H and T3I) in the SETX gene 
have been detected in 3 unrelated families. All affected individuals from 3 pedigrees 
were heterozygous for the missense substitution, confirming the autosomal dominant 
pattern of inheritance (121). Recently Zhao et al. identified a novel variation, Thr1118Ile, 
in a 42‑year‑old individual with sporadic ALS. This study shows that Senataxin might 
be associated with sporadic ALS and that the possible clinical phenotypes of Senataxin 
mutations may be wider than originally considered (126).
Angiogenin (ANG)
The ANG gene, on chromosome 14q11, is composed of two exons, of which only one 
coding. ANG, a 123‑residue protein, is a potent inducer of neovascularisation in vivo 
and a member of the pancreatic ribonuclease A (RNase A) superfamily (127).
The ANG protein plays a role in inhibiting of protein translation by cleaving tRNA 
and helps in rRNA biogenesis and cellular proliferation (128). ANG is synthesized 
with a signal peptide of 24 amino acids that is cleaved to form the mature protein. 
The RNase activity of ANG is important for its biological activity, and ANG variants with 
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decreased RNase activity invariably have reduced 
angiogenic activity (129).
ANG is expressed in the neuroaxis; however, 
its mechanism of action is yet to be established. 
In endothelium, ANG organizes cell formation 
into tube‑like structures, induces secondary 
messengers and supports endothelial cell adhesion 
and spreading. In steps that are critical for 
angiogenesis, ANG is internalized by endothelial 
cells and transported to the nucleolus (128), where 
it stimulates rRNA transcription, a rate‑limiting 
step in ribosome biogenesis, protein translation 
and cell growth. ANG shares a metabolic pathway 
with vascular endothelial growth factor (VEGF), 
which is implicated in ALS (127). ANG mediates 
neovascularisation and promotes neurite outgrowth during early embryonic 
development. Mutations in ANG gene cause loss of ribonucleolytic activity and nuclear 
translocation activity (130).
In 2006 Greenway et al. identified 5 missense mutations in 11 Scottish or Irish 
individuals with ALS that affect functionally important residues (Q12L, K17I, 
K17E, C39W and K40I), evolutionarily highly conserved in ANG, RNase or both 
(Figure 11) (127). Lys40 in ANG is a critical residue involved in catalysis. Molecular 
modelling of the K40I substitution suggests that several key interactions are lost 
owing to mutation, predicting loss of ribonucleolytic activity. C39W causes substantial 
structural change owing to loss of disulfide bridge formation with Cys92. Disruption of 
this disulfide bridge is likely to affect protein folding, resulting in lower ribonucleolytic 
activity. Gln12 interacts with the active site residue Lys40 in the native structure 
and the Q12L substitution would disrupt this interaction and make the protein 
enzymatically less active. It is unlikely that variants K17I or K17E have a substantial 
effect on the structure, because of Lys17 in ANG is distant from the active site, in a 
loop on the surface of the molecule. However it was previously demonstrated that a 
conserved region containing Lys17 is involved in the activity of ANG against intact 
proportion (60%) of individuals with ANG mutations had bulbar
onset disease.
Common haplotypes were observed across the ANG locus and
flanking region in Irish and Scottish individuals with K17I (indivi-
duals S3 and S4) and K40I (S8, S9 and S10) mutations, indicative of a
founder effect (Supplementary Table 3 online). We identified a
unique shared haplotype for the K17E mutation in individuals of
Swedish and Northern Irish ethnicity (S5 and S6).
ANG, a 123-residue, 14.1-kDa protein, is a potent inducer of
neovascularization in vivo and a member of the pancreatic ribonu-
clease A (RNase A) superfamily3. ANG is synthesized with a signal
peptide of 24 amino acids that is cleaved to form the mature protein.
The RNase activity of ANG is important for its biological activity,
and ANG variants with decreased RNase activity invariably have
reduced angiogenic activity4,5. ANG is expressed in the neuroaxis.
However, its mechanism of action is yet to be established. In
endothelium, ANG organizes cell formati n into tube-like structures,
induces secondary messengers and supports endothelial cell adhesion
and spreading. In steps that are critical for angiogenesis, ANG is
internalized by endothelial cells and transported to the nucleolus6,
where it stimulates rRNA transcription, a rate-limiting step in ribo-
some biogenesis, protein translation and cell growth. Endogenous
ANG is required for cell proliferation induced by other angiogenic
proteins such as vascular endothelial growth factor (VEGF)7. Down-
regulation of ANG by small interfering RNA (siRNA) and antisense
oligonucleotides decreases VEGF-induced rRNA transcription, and
inhibition of nuclear translocation of ANG abolishes the angiogenic
activity of VEGF7.
Crystal structure analysis of ANG has provided clear evidence of an
RNase A fold and conservation of His13, Lys40 and His114—the
catalytic triad8. Five of the missense mutations identified in 11
individuals with ALS affect functionally important residues (Q12L,
K17I, K17E, C39W and K40I) that are evolutionary highly conserved
in ANG, RNase A or both (Fig. 1b). Lys40 in ANG is a critical residue
involved in catalysis. Replacement of Lys40 by glutamine, or a
conservative substitution by arginine, decreases the ribonucleolytic
activity by a factor 42  103 or 50-fold, respectively4. Molecular
modeling of the K40I substitution suggests that several key interac-
tions are lost owing to mutation, predicting loss of ribonucleolytic
activity (Fig. 1b and Supplementary Table 4 online). C39W causes
substantial structural change owing to loss of disulfide bridge forma-
tion with Cys92 (Fig. 1b and Supplementary Table 4). Disruption of
this disulfide bridge is likely to affect protein folding, resulting in
lower ribonucleolytic activity. Gln12 interacts with the active site
residue Lys40 in the native structure (Fig. 1b and Supplementary
Table 4). Q12L substitution would disrupt this interaction and make it
enzymatically less activ . Resi ue Lys17 in ANG is distantly positioned
from the active site in a loop on the surface of the molecule (Fig. 1b).
It is unlikely that varia ts K17I or K17E have a substantial effect on
the structure (Supplementary Table 4). However, a previous study on
an ANG-RNase A hybrid demonstrates that a conserved region
containing Lys17 is involved in the activity of ANG against intact
ribosomes. This suggests that isoleucine or glutamate variants of Lys17
may alter ANG activity9.
In addition to the catalytic center, ANG possesses a nuclear
translocation site that contains a sequence (31-RRRGL-35) involved
in transport of ANG to the nucleolus after uptake by endothelial cells.
R31A is translocated much less efficiently than the native protein10.
We predict that the R31K variant may have a role in nuclear
translocation but would cause only minor perturbation in the
structure. Ile46 is not fully conserved, and replacement of this residue
by valine is predicted to cause little structural change.
Like VEGF, ANG is induced by hypoxia to elicit angiogenesis4,5
and is expressed in motor neurons11 (Supplementary Figs. 1 and 2
and Supplementary Methods online). Deletion of the hypoxic
response element of the VEGF promoter causes a motor neuron
disease phenotype in mice12, and replacement of VEGF is benefi-
cial in SODG93A rodent models13,14. At-risk haplotypes in the
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Figure 1 ANG mutations in ALS. (a) Pedigrees for selected patients with ANG mutations. Mutations are indicated using single letter amino acid code.
Probands are indicated by arrows; circle, female; square, male; open symbol, unaffected; shaded symbol, affected; diagonal line, deceased; Co, control;
asterisk, mutation. Current age, or age at death and cause of death, is indicated. Dmt, dementia; MI, myocardial infarction. (b) Three-dimensional structure;
of ANG showing the modeled mutations Q12L, K17E, K17I, R31K, C39W, K40I and I46V in ball-and-stick representation. The figure was created using the
program PyMOL (DeLano Scientific).
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Figure 11. Three‑dimensional 
structure of ANG showi g the 
modeled mutations Q12L, K17E, 
K17I, R31K, C39W, K40I and I46V 
in ball‑and‑stick representation
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ribosomes. This suggests that isoleucine or glutamate variants of Lys17 may alter 
ANG activity (127,131).
As for two others variants found in the cohort of patients: the R31K variant may have a 
role in nuclear translocation but would cause only minor perturbation in the structure, 
whereas Ile46 is not fully conserved, and replacement of this residue by valine is 
predicted to cause little structural change.
Finally Greenway found ANG mutations as a clear susceptibility factor for the 
development of ALS, particularly in individuals of Irish and Scottish descent. Greenway 
in the 2004 have also reported an association of ALS with the rs11701 (G110G) SNP in 
the Irish and Scottish population with ALS, although no association was observed in the 
populations from the US, England, Sweden (132) or Italy (133).
Only the study of Conforti et al. reveals an association between FALS and rs11701 
SNP in ANG gene, but not in SALS patients. Further investigations on the relationship 
between angiogenic genes and ALS are needed (134).
Aim of the study
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Amyotrophic lateral sclerosis (ALS) is a complex disorder. Both genetic and 
environmental factors are known to contribute to it. The discovery of mutations in 
SOD1 as causative of familial ALS (135), in 1993, started the molecular genetics era of 
ALS research. Over the last 20 years an increasing number of causative genes have 
been identified, revealing a high degree of genetic heterogeneity. The pathogenic 
hexanucleotide repeat expansion in chromosome 9 open reading frame 72 (C9ORF72) 
is currently known as the most relevant genetic risk factor for ALS.
The combination of a genetic risk factor with a large effect with another mutation with 
incomplete penetrance fits well the oligogenic disease model. An oligogenic aetiology 
should be considered in genetic counselling, especially of unaffected family members.
For all these reasons, aim of the present study is the molecular characterization of the 
C9ORF72, SOD1, TARDBP and FUS genes in a group of Italian ALS patients, with a 
definite/probable/possible disease diagnosis.
All the enrolled ALS patients were divided in familial ALS (FALS) and sporadic ALS 
(SALS). FALS patients underwent first genetic counselling. All mutated subjects 
were communicated the result of the genetic test within a multidisciplinary context 
(neurologist, psychologist, geneticist). The at risk family members of ALS mutated 
subjects were also evaluated in a multidisciplinary context, to assess their purpose to 
undergo genetic testing.
Frequency of C9ORF72, SOD1, TARDBP and FUS mutations in our Italian cohort 
of patients was evaluated in order to verify data collected by other Italian studies. 
Moreover we studied all the ALS associated genes in order to confirm the oligogenic 
model on our cohort of patients.
In addition, for some patients with specific phenotype features, we analysed specific 
genes (SETX, GRN, VCP). To explore the phenotypic heterogeneity within the 
families, we also investigated the possible relationship between the ALS causative 
gene mutation and other modifier genes reported to be involved in ALS pathogenesis, 
such as ANG, PON1, PON2, VEGF, MTHFR, APOE, HFE.
Material 
& methods
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Patients
Our cohort of ALS patients attended the NEuroMuscular Omnicenter (NEMO), 
a specialized centre for the study and treatment of neuromuscular diseases. 
This centre is located within one of the most important hospitals in Italy, Niguarda Ca’ 
Granda Hospital, which is a national and international benchmark for many diseases, 
including rare diseases.
ALS diagnosis requires a set of neurological analyses repeated over time and a 
number of different medical examinations to exclude other neurological disorders 
(differential diagnosis).
The laboratory and clinical studies below are helpful in confirming the diagnosis, 
and ruling out other possible diseases.
• Biochemical tests: blood tests for people suspected of having ALS are routine 
laboratory tests. Usually ALS patients will not show any abnormalities within 
their blood, but blood tests are conducted to show that no other disease is 
present that is being mistaken for ALS. A blood test will check blood cell count, 
hormone levels, as well as liver and kidney function and detect if any infections 
are present. In ALS CK (creatine kinase) may be normal or moderately elevated 
(2‑3 times normal) indicating the impairment of muscle.
• Electromyography: the signs of fibrillation or positive waves (together referred 
to as spontaneous activity) and a decreased recruitment in a muscle, qualified 
as lower motor neuron findings, can be used to upgrade the probability of the 
diagnosis of ALS.
• Magnetic resonance imaging (MRI) of the spine: this test uses powerful 
magnets and radio waves to produce a detailed view of the nervous system. 
Multi‑focal spine disease can mimic the findings of ALS and therefore should be 
ruled out with an anatomical study.
• Muscle biopsy: it is not routinely performed, but is done in selected cases in 
which the diagnosis is problematic. In ALS, a muscle biopsy will show neurogenic 
atrophy. It is useful to determine if the patient has a muscle disorder (myopathy), 
such as myositis or muscular dystrophy, rather than ALS.
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• Spinal tap (lumbar puncture): it is rarely necessary to exclude other 
neurological disorders such as primary lateral sclerosis, multi‑focal motor 
neuropathy, Kennedy disease, myasthenia gravis and spinal muscular atrophy. 
A lumbar puncture can help diagnose serious infections, such as meningitis; 
disorders of the central nervous system, such as Guillain‑Barrè syndrome and 
multiple sclerosis; or cancers of the brain or spinal cord.
Therefore the diagnosis of ALS is based primarily on clinical presentation, with 
supportive data from electrodiagnostic, imaging and laboratory studies.
Our cohort of ALS cases includes 302 subjects with definite/probable/possible 
diagnosis of ALS according to the previously described El Escorial criteria. 
The selected ALS patients are 17 FALS (5.6%) and 285 SALS (94.4%), respectively. 
All patients included in this study were subjected to a specific integrated procedure 
of genetic counselling. The main steps are summarized in Figure 12.
Flow chart genetic counseling
Identification of affected ALS patient
Pre-test 
Questionnaire 2
After 2 ½ months
of blood sampling
After 4 months
of blood sampling
Follow-up
Questionnaire 3
  
After 6 months
of blood sampling Follow-upQuestionnaire 4
  
Reporting of the case (mail, phone etc.)
1. Members of the team presentation
2. Discussion of the genetic aspect
3. Evaluation of the physicological profile
Meeting of the team
 +
 index case and family
Psychological assesment:
interview and submission
of questionnaires
Psychological
suppport
Optional
psychological
suppport
Negative
TEST
Positive
TEST
Informed consent + blood sampling
Meeting of the team about the genetic results
Eventually extending analysis
to family members
Pre-test 
Questionnaire 1
Figure 12. This flow‑chart set up by our team in Niguarda Ca’ Granda Hospital shows the steps 
to arrive at optimal clinical definition and management of ALS patients
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Genetic counselling 
Genetic counselling is a communication process related to the occurrence or risk of 
an inherited disease. Genetic counselling aims at educating individuals about disease, 
including the nature of inheritance; and at facilitating understanding of genetic testing 
options for confirmation of disease. Assessing family history is a key component of 
genetic counselling. The geneticist should obtain a detailed three‑generation pedigree 
that captures the presence of FTD, ALS, other dementias and Parkinsonism or other 
neurological or non‑neurological disorders. The pedigree should include ages and 
site of disease onset, diagnosis and ages at death. Particularly important is to identify 
precisely the geographical origin of the family. Therefore pre‑test genetic counselling 
should help individuals to appreciate the risks, benefits and limitations of testing.
Informed consent
Every proband and all the family members who decided to participate in this study were 
offered genetic test and counselling, and all signed the informed consent approved by 
the ethics committee of our hospital (Figure 13).
Figure 13.  Informed consent
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DNA extraction from whole blood
DNA extraction with salting‑out procedure
DNA was extracted from whole blood of all the ALS patients with the salting‑out 
procedure (136). This method avoided using the hazardous organic solvents phenol 
and chloroform and involved salting out of the cellular proteins by dehydration and 
precipitation with a saturated NaCl solution. Average yields were similar to those 
obtained with the phenol‑chloroform extraction procedure (50‑200 μg), and the quality 
of DNA was excellent.
The procedure consisted of the following steps:
1. each whole blood sample was thawed; 2 to 4 mL of whole blood were placed in 
a 50 mL tube together with 45 mL of lysis buffer (20 mM Tris/HCl, 5 mM EDTA, 
pH 7.8‑8) stored at 4 °C;
2. a centrifugation at 3500 rpm for 20 minutes at 4 °C was performed;
3. the surnatant was discarded and the pellet was resuspended in 40 mL 
of lysis buffer;
4. a centrifugation at 3500 rpm for 20 minutes at 4 °C was performed;
5. steps 3) and 4) were repeated until the pellet was clear;
6. the pellet was resuspended in 10 mL of lysis buffer; 400 μL of 10% SDS 
(0.4 % in the final volume) and 150 μL of 10 mg/mL proteinase K were added; 
the tube was shaken vigorously till foam formation;
7. the tube was incubated overnight at 37 °C;
8. 3.3 mL of 5 M NaCl were added and the solution was shaken;
9. a centrifugation at 3500 rpm for 15 minutes at room temperature was performed;
10. the pellet was carefully transferred into a new 50 mL tube containing 30 mL 
of 99% ethanol stored at ‑20 °C;
11. the tube was gently inverted several times until DNA precipitated; precipitated 
DNA strands were removed with a plastic spatula, washed with 70% ethanol 
(stored at ‑20 °C) and transferred in a 1.5 mL tube;
12. after ethanol evaporation, DNA was suspended in 150 to 200 μL of dd H2O.
DNA obtained with this procedure was stored at 4 °C until its use.
50
DNA extraction with QIAGEN kit
DNA was re‑extracted from whole blood of mutated subjects using the QIAamp® DNA 
Blood Mini Kit (QIAGEN); the procedure comprised 4 steps and was automated on 
the QIAcube (QIAGEN) (Figure 14), an instrument that uses advanced technology 
to process QIAGEN spin columns, enabling seamless integration of automated, 
low‑throughput sample preparation. Up to 12 samples could be processed per run. 
The principle of the QIAcube extractor is based on the lysis and elimination of red 
blood cells and on the subsequent extraction of genomic DNA from leukocytes through 
cells lysis by using an anionic detergent. Contaminating RNA is removed by enzymatic 
treatment, while other contaminants, such as proteins, are eliminated by separation on 
pre‑packed columns.
BA
Figure 14. QIAcube instrument. A. The outside. B. The inside.
Sample preparation using QIAcube followed the same 4 steps as the manual spin 
procedure (Figure 15). Each whole blood sample was thawed and 200 μL were used 
for DNA extraction in order to obtain about 3‑12 μg of DNA. Briefly, optimized buffers 
lysed samples, stabilized nucleic acids and enhanced selective DNA adsorption to 
the QIAamp membrane. Alcohol was added and lysates were loaded onto the spin 
columns. DNA was adsorbed onto the silica membrane during a brief centrifugation. 
Salt and pH conditions in the lysate ensured that proteins and other contaminants, 
which could inhibit PCR and downstream enzymatic reactions, were not retained on 
the membrane. DNA bound to the membrane was washed in two centrifugation steps 
by using two different wash buffers; wash conditions ensured the complete removal of 
any residual contaminants without affecting DNA binding. Purified DNA was then eluted 
from the spin column in a concentrated form in a low salt buffer (100 μL final volume).
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The concentration of DNA extracted following the two  
different procedures described before was checked by 
spectrophotometry; DNA purity was assessed through  
λ260/λ280 ratio (expected ratio ca. 1.75). The integrity of 
each DNA sample was verified through electrophoresis on a 
0.5% agarose gel. In order to prepare a 100 mL solution, 
0.5 g of agarose were weighed and added to 100 mL of TAE 
buffer (10 mM Tris/HCl, pH 8.0, 1 mM EDTA); the solution 
was then brought to the boil until it was limpid. After cooling, 
8 μL of GelRed™ 10000X (Biotium) were added; this red 
fluorescent nucleic acid dye can be excited with a common 
300 nm UV transilluminator. One microlitre of each sample 
genomic DNA was mixed with 7 μL of H2O and 2 μL of a gel 
loading buffer (GelPilot DNA Loading Dye 5X, QIAGEN), 
and the samples were loaded into the gel wells. For sizing 
of genomic DNA, a DNA ladder (1 kb Molecular Ruler, 
BIORAD), previously diluted 1:4, was always added in each 
electrophoretic gel, in a position adjacent to that of the DNA samples under verification. 
1 kb DNA ladder contained fragments of 15, 7, 6, 5, 4, 3, 2, 1 kb. DNA was stored at 
4 °C until its use.
DNA amplification
Extracted DNA was amplified by means of Polymerase Chain Reaction (PCR). Primers 
were designed to amplify the 5 exons and the corresponding intron/exon boundaries of 
SOD1 and FUS genes. Moreover primers were designed for exon 6 of TARDBP and for 
promoter, exon 1 and exon 2 of ANG gene and their intron/exon boundaries. Specific 
protocols were developed in our laboratory in order to amplify the largest number of 
exons with the same protocol. Because of their length, both promoter and exon 2 of 
ANG gene as well as TARDBP exon were divided into two parts and amplified with the 
same PCR reaction. In some case other genes were screened (SETX, GRN, VCP) by 
using previously described primers (126,137,138).
Sample
Lyse
Bind
Wash
(2 step)
Elute
Pure genomic DNA
Figure 15. Schematic 
representation of the 
spin procedure for 
DNA extraction by 
using the QIAamp® 
DNA Blood Mini Kit
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Table 5 shows the length of PCR products and some characteristics of the primers 
(sequence, melting temperature) used in each PCR amplification.
S
O
D
1
Exon Primer forward Primer reverse
PCR 
products 
(bp)
Tm 
(°C)
1 5’‑GCG‑ATT‑GGT‑TTG‑GGG‑CCA‑GAG‑3’
5’‑ACC‑CGC‑CTC‑CAT‑GCA‑
AAA‑GGT‑TGC‑3’ 259 57
2 5’‑ACT‑CTC‑TCC‑AAC‑TTT‑GCA‑CTT‑3’
5’‑CGT‑TTA‑GGG‑GCT‑ACT‑CTA‑
CT‑3’ 261 57
3 5’‑CAT‑AAT‑TTA‑GCT‑TTT‑TTT‑TTC‑TTC‑TTC‑3’
5’‑ACG‑GAA‑TTA‑TCT‑TAG‑GCA‑
CAT‑A‑3’ 258 57
4 5’‑GCA‑TCA‑GCC‑CTA‑ATC‑CAT‑CTG‑3’
5’‑CGC‑GAC‑TAA‑CAA‑TCA‑
AAG‑TGA‑A‑3’ 276 57
5 5’‑AGT‑GAT‑TAC‑TTG‑ACA‑GCC‑CAA‑AG‑3’
5’‑CTA‑CAG‑CTA‑GCA‑GGA‑TAA‑
CAG‑ATG‑3’ 257 57
TA
R
D
B
P
Exon Primer forward Primer reverse
PCR 
products 
(bp)
Tm 
(°C)
6a 5’‑TGC‑TTG‑TAA‑TCT‑AAG‑TTT‑TGT‑TGC‑ 3’
5‑GCT‑GGC‑TGG‑CTA‑ACA‑
TGC‑3’ 401 56
6b 5’‑GG‑TGG‑GAT‑GAA‑CTT‑TGG‑TG‑3’ 
5’‑TGC‑TGA‑ATA‑TAC‑TCC‑ACA‑
CTG‑AAC‑3’ 457 56
FU
S
Exon Primer forward Primer reverse
PCR 
products 
(bp)
Tm 
(°C)
5 5’‑TGT‑TGG‑GTA‑CAG‑AGA‑ATG‑GAC‑TCC‑AC‑3’
5’‑AAA‑TGG‑GCT‑GCA‑GAC‑
AAA‑GCT‑G‑3’ 314 60
6 5’‑CCT‑GGC‑ACT‑TGT‑CAA‑ACC‑TT‑3’
5’‑GCA‑CTA‑GGG‑ACT‑GGC‑
TTC‑AG‑3’ 414 60
13/14 5’‑GTC‑ACC‑GTA‑GTT‑TCT‑TCC‑TAG‑TTC‑TAG‑3’ 
5’‑AAC‑CCT‑GTT‑ATC‑CTA‑TGG‑
CCT‑CTG‑T‑3’ 511 60
15 5’‑GAC‑CCA‑CTT‑GAG‑ATA‑AGA‑TAC‑TCG‑CT‑3’ 
5’‑TCT‑ACC‑TTC‑CTG‑ATC‑GGG‑
ACA‑TCG‑A‑3’ 389 60
A
N
G
Exon Primer forward Primer reverse
PCR 
products 
(bp)
Tm 
(°C)
Pro1 5’‑GCT‑GTC‑GAC‑CAG‑TGT‑CAA‑GA‑3’ 
5’‑GTG‑CCA‑GCC‑TCT‑GCG‑
TAG‑T‑3’ 320 55
Pro2 5’‑GCG‑GAA‑AAG‑AGA‑AAT‑TCA‑GA‑3’ 
5’‑GGG‑AAA‑CTG‑GCT‑TCT‑
GCT‑3’ 357 55
1 5’‑CGG‑TCC‑CAA‑CTA‑CGC‑AGA‑3’
5’‑GAG‑TCC‑CAA‑GCT‑GCC‑
TCT‑AC‑3’ 343 55
2A 5’‑GCA‑AAG‑CTC‑CTG‑TCC‑TTT‑TG‑3’
5’‑CGC‑TTG‑TTG‑CCA‑TGA‑ATA‑
AA‑3’ 318 55
2B 5’‑GAA‑AGC‑ATC‑ATG‑AGG‑AGA‑CG‑3’
5’‑GAA‑TGT‑TGC‑CAC‑CAC‑TGT‑
TC‑3’ 378 55
Abbreviations: bp, base pairs; Tm, melting temperature.
Table 5. PCR products lengths, primer sequences and melting temperatures (Tm)
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All reagents used for PCR amplifications were provided by Euroclone. Each PCR 
reaction was performed in a total volume of 12.5 μL (PCR mixture).
PCR mixture used to amplify 5 exons of SOD1 gene as well as exon 6 of TARDBP 
gene and ANG gene contained:
• 4.475 μL H2O
• 2.25 μL 50% Gly
• 1.25 μL PCR reaction Buffer 10x (Mg++ free)
• 0.375 μL 50 mM MgCl2
• 1 μL 2.5 mM dNTPs
• 1 μL 10 μM primer forward
• 1 μL 10 μM primer reverse
• 0.15 μL Red®Taq 5U/μL DNA Polymerase
• 1.0 μL genomic DNA
PCR mixture used to amplify 5 exons of FUS gene contained:
• 7.225 μL H2O
• 1.25 μL PCR reaction Buffer 10x (Mg++ free)
• 0.375 μL 50 mM MgCl2
• 1 μL 2.5 mM dNTPs
• 1 μL 10 μM primer forward
• 1 μL 10 μM primer reverse
• 0.15 μL Red®Taq 5U/μL DNA Polymerase
• 0.5 μL genomic DNA
A single program on a thermal cycler (GeneAmp® PCR System 9700, Applied 
Biosystems) was used for all the PCR amplifications: 
• 1 cycle at 96 °C for 10 minutes, to ensure the complete denaturation of template 
DNA and the activation of the polymerase;
• 35 cycles, each one composed of: 95 °C for 30 seconds (DNA denaturation) 
– 55/56/57/60 °C for 60 seconds (primers annealing) – 72 °C for 60 seconds 
(DNA extension);
• 1 cycle at 72 °C for 5 minutes to fill‑in the protruding ends of reaction products.
The annealing temperature changed depending on the gene and the exon to be 
amplified.
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For each amplification protocol, a negative control was used: it consisted of a PCR 
mixture aliquot with no DNA added. Negative control had to give no PCR products and 
was indicative of the presence or absence of contamination in the reaction. Once the 
amplification was completed, agarose gels were prepared in order to test the quality of 
the PCR products.
Agarose gel could be prepared at different percentages to allow the separation of PCR 
products on the basis of their lengths, expressed as base pairs. For the confirmation 
of our PCR products, a 2% agarose gel was sufficient (gel preparation is described 
in the section “DNA extraction with QIAGEN kit”). Three microlitres of amplified DNA 
were mixed with 2 μL of the gel‑loading buffer previously diluted 1:2, and the samples 
were loaded into the gel wells. For sizing the PCR products (217 to 314 bp), a DNA 
ladder (GeneRuler™ 100 bp DNA Ladder, Genenco) was always used; it contained 
the following 11 discrete fragments: 1031, 900, 800, 700, 600, 500, 400, 300, 200, 100 
and 80 bp.
The amplification protocol for  
SOD1, FUS, and ANG was 
performed using Biomek NXP. 
Biomek NXP (Beckman Coulter) 
puts every aspect of liquid 
handling, including pipetting, 
dilution, dispensing and 
integration, into a single, 
automated system that is as 
powerful and flexible as it is 
efficient and economical 
(Figure 16).
Biomek NXP offers proven pipetting performance for low‑volume reaction setup and 
assay miniaturization, as well as accurate and repeatable results extending into the 
submicrolitre range. Since many functions are combined into a single step, setup is fast 
and effortless.
 Automation of reaction setup can also eliminate both human error and contamination 
associated with manual processing, while assuring high quality results. The reliability of 
Figure 16. Biomek NXP (Beckman Coulter)
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this instrument, repeatable pipetting, tube to plate capability and an efficient automation 
combine to provide an ideal automation solution for the amplification protocol. 
Moreover its low‑volume capability helps miniaturize reaction setups and save on 
costly reagents.
Biomek NXP combined with robust Biomek Software is used to manage and program 
the instrument (Figure 17). This software provides the ability to customize the interface 
setting for every PCR step, as type of tip to use, source and destination of reagents 
and it is able to configure methods with drag‑and‑drop ease. The users have only to 
prepare the worktop with tips, reagents, tubes, primers, DNA and plate of destination in 
the correct position.
Figure 17. Software interface of Biomek NXP
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Purification of PCR products
Automated
Amplicons have to be purified to eliminate excess oligos, nucleotides, salts, enzymes 
and other contaminants that may inhibit subsequent reactions. The purification was 
performed using AMPure® PCR Purification Kit (Agencourt® Bioscience Corporation) 
(Figure 18) and automating the process through Biomek 3000 (Beckman Coulter). 
The Agencourt AMPure method utilizes Solid Phase Reversible Immobilization (SPRI) 
magnetic bead‑based technology, which requires no centrifugation or filtration.
The Agencourt AMPure purification process binds PCR amplicons to para‑magnetic 
particles and draws them out of solution, allowing contaminants such as primers, 
primer dimers, salts, and dNTPs to be easily rinsed away providing purified PCR 
product ideal for downstream genomics applications. The para‑magnetic particles are 
constituted for 40% of magnetite and have uniform size (1 μm); their negative charge 
binds PCR products 100 bp and larger. Placed in a magnetic field, the amplicons 
remain bound to the magnetic beads in the plate wells, while the washes are performed 
and the contaminants removed. At the end the purified DNA is eluted with dd H2O and 
transferred to another plate.
Figure 18. Schematic representation of PCR purification
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The AMPure procedure is performed in 8 steps:
1. mix AMPure reagent with the PCR reaction mixture. Add 1.8 μL AMPure per 
1.0 μL of PCR product;
2.  bind PCR products to para‑magnetic beads and incubate for 3‑5 minutes;
3. move the plate on the magnetic support, incubate for 5‑10 minutes to separate 
beads from solution;
4. aspirate the cleared solution from the reaction plate and discard;
5. dispense 200 μL of 85% ethanol to each well of the reaction plate and incubate 
for 30 seconds at room temperature; aspirate out the ethanol and discard; 
repeat for a total of two washes;
6. place the reaction plate on bench top to air‑dry; the plate should be left for 
10‑20 minutes to allow complete evaporation of residual ethanol that may inhibit 
the subsequent reactions;
7. add 40 μL of dd H2O to each well of the reaction plate and mix in order to elute 
purified PCR product from the beads;
8. transfer the purified products to a new plate.
This process has been automated and optimized by using the Biomek 3000 
(Beckman Coulter) (Figure 19). This instrument is an automated laboratory workstation 
fully compatible with Agencourt AMPure.
As for the Biomek NXP,  
Biomek 3000 automates 
many processes. This 
instrument has a mechanical 
arm that moves on 3 axes 
(X, Y, Z) mono and 
multichannel pipettes (P20, 
MP20, P200, MP200, P1000) 
besides the gripper tool that 
picks up and dislocates the 
plates. On the worktop there 
is space to accommodate the magnetic support as well as containers for reagents, 
plates, tips and waste. User‑friendly software facilitates tailoring each protocol to 
specific requirements, or building new protocols from scratch. The user must have the 
material correctly placed on the worktop, as indicated on the program, and start it.
Figure 19. Biomek 3000 (Beckman Coulter)
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Manual
The purification of PCR products was performed by using the QIAquick® PCR 
Purification Kit (QIAGEN) that combines the convenience of spin‑column technology 
with the selective binding properties of a uniquely designed silica membrane. DNA 
adsorbs to the silica membrane in the presence of high concentrations of salts, while 
unwanted primers and impurities, such as enzymes, unincorporated nucleotides, 
agarose, oils and detergents pass through the column. Contaminants are efficiently 
washed away, and the pure DNA is eluted with Tris buffer.
For the PCR products purification, the protocol described  
below was followed (Figure 20):
1. 5 volumes of PBI buffer (binding buffer) were added 
to 1 volume of the PCR sample and mixed;
2. a QIAquick spin column was placed in a 2 mL 
collection tube;
3. the sample was applied to the spin column 
and centrifuged at 14000 rpm for 60 seconds;
4. the eluate was discarded and the spin column 
was placed back in the same tube;
5. 0.75 mL of PE buffer (washing buffer) was added 
to the column and a centrifugation at 14000 rpm 
for 60 seconds was performed;
6. after discarding the eluate and placing back the spin 
column in the same tube, a centrifugation at 14000 rpm 
for additional 60 seconds was carried out;
7. the column was placed in a clean 1.5 mL 
centrifuge tube;
8. 30 μL of EB buffer (elution buffer) were added to the centre of the membrane 
and, after an incubation time of about 60 seconds, a centrifugation at 14000 rpm 
for 60 seconds was performed.
Purified DNA fragments were quantified in order to settle the suitable quantity of DNA to 
use in the subsequent sequencing reaction. DNA yield was determined by 2% agarose 
Figure 20. Schematic 
representation of the 
spin procedure for PCR 
products purification 
by using the QIAquick® 
PCR Purification Kit.
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gel analysis: the same procedure described in “Confirmation of PCR Products” was 
used. The amount of loaded DNA sample was estimated by visual comparison of the 
band intensity with that of the standards (GeneRuler™ 100 bp DNA Ladder, Genenco); 
DNA quantity for a correct sequencing reaction is 10 ng per 100 bp. Purified PCR 
products were stored at 4 °C until their use.
Sequencing analysis
Sequencing a DNA fragment amplified by PCR allows its nucleotide sequence to be 
determined, individualizing the possible presence of a variation. The most commonly 
used approach is the dideoxy chain termination method (Sanger method) (139). The key 
principle of the Sanger method is the use of dideoxynucleotide triphosphates (ddNTPs) 
as DNA chain terminators: they are analogues of the normal dNTPs, but differ in that 
they lack a hydroxyl group at the 3’ carbon 
position as well as at the 2’ carbon. Lacking this 
group, any ddNTP that is incorporated into a 
growing DNA chain cannot participate in 
phosphodiester bonding at its 3’ carbon atom, 
thereby causing abrupt termination of chain 
synthesis. Competition for incorporation into the 
growing DNA chain between a ddNTP and its 
normal dNTP analogue results in a population of 
fragments of different lengths (140). The technique 
requires a single‑stranded DNA template, a DNA 
primer and a sequencing kit containing DNA 
polymerase, dNTPs and the four ddNTPs labelled 
with fluorescent dyes, each of which with different 
wavelengths of fluorescence and emission. 
The newly synthesized and labelled DNA 
fragments are heat denatured and separated by 
size by capillary electrophoresis (CE).
Figure 21. Schematic representation 
of the automated DNA sequencing 
with capillary electrophoresis  
(www.appliedbiosystems.com)
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During CE, the DNA fragments are electrokinetically injected into capillaries filled with 
a high‑resolution polymer. High voltage is applied so that the negatively charged DNA 
fragments move through the polymer toward the positive electrode. CE can resolve 
DNA molecules that differ in molecular weight by only one nucleotide. Shortly before 
reaching the positive electrode, the fluorescently labelled DNA fragments move through 
the path of a laser beam that causes the dyes on the fragments to fluoresce. An optical 
detection device detects the fluorescence; specific software converts the fluorescence 
signal to digital data and records them (Figure 21). Since each dye emits light at a 
different wavelength when excited by the laser, all four colours, and therefore, all four 
bases, can be detected and distinguished in one capillary injection (Figure 22).
Figure 22. Electropherogram (www.appliedbiosystems.com)
Automated and manual sequencing reaction protocol
The sequencing reaction was performed by using the BigDye Term Cycle Seq Kit 
(Applied Biosystems). Version 1.1 was used for SOD1 and ANG gene, while version 
3.1 for FUS gene.
When automated on Biomek 3000, each protocol involved the use of:
• 1 μL of 10 μM primer forward or reverse;
• 1 μL of DNA sequencing Mix;
• 2 μL of BigDye® Terminator v1.1 5X Sequencing Buffer;
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• DNA quantity established following the procedure “Confirmation of PCR products” 
(usually 1 μL of amplified DNA was used);
• H2O to a final volume of 10 μL.
Only for TARDBP gene the sequencing reaction protocol was performed in a manual 
mode, possibly in a dark room, using BigDye v3.1.
Each protocol involved the use of:
• 1 μL of 10 μM primer forward or reverse;
• 2 μL of DNA sequencing Mix;
• DNA quantity established following the procedure “Confirmation of PCR products 
(usually 2 to 3 μL of amplified DNA were used);
• H2O to a final volume of 20 μL.
Each exon of each gene was sequenced on both strands; therefore two sequencing 
reactions, one with primer forward and the other with primer reverse, were performed.
For the sequencing reaction with BigDye v3.1, the following program on the thermal 
cycler was performed:
• 1 step at 96 °C for 1 minute;
• 25 cycles, each one composed of: 96 °C for 10 seconds (DNA denaturation) – 
50 °C for 5 seconds (primer annealing) – 60 °C for 4 minutes (DNA extension).
For the sequencing reaction with BigDye v1.1 the program is devoid of the first step. 
Purification of sequencing reaction products
Automated
It was necessary to purify the sequencing reaction products in order to remove 
unincorporated dye terminators and all the other reagents and by‑products. Removal of 
unincorporated dye‑terminators is required prior to capillary electrophoresis, because 
they can cause a “background noise” which makes the electropherograms unreadable. 
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The CleanSEQ Sequencing Reaction Clean‑Up has proven an efficient and highly 
effective dye‑terminator removal system with the ABI 3730 sequencer. This system 
utilizes Agencourt’s patented SPRI™ para‑magnetic bead technology as in the AMPure 
purification process previously described.
Also in this case, the process is automated through Biomek 3000 (Beckman Coulter). 
The protocol can be performed directly in the thermal cycler plate. CleanSEQ contains 
magnetic particles in an optimized binding buffer to selectively capture sequencing 
extension products, whereas unincorporated dyes, nucleotides, salts and contaminants 
are removed using a simple washing procedure.
Figure 23. Schematic representation of CleanSEQ purification
The CleanSEQ procedure is performed in 7 steps: 
1. gently shake the CleanSEQ bottle to re‑suspend any magnetic particles that 
may have settled. Add 10 μL of CleanSEQ to the reaction plate;
2. add 42 μL of 85% ethanol to the reaction plate; pipette the mix 7 times;
3. place the reaction plate onto magnetic support for 3 minutes to separate beads 
from solutions;
4. aspirate the cleared solution from the reaction plate and discard;
5.  dispense 100 μL of 85% ethanol and incubate at room temperature for at 
least 30 seconds, then aspirate out the ethanol and discard; repeat for a total 
of 2 washes;
6. let the reaction plate air‑dry for 10 minutes at room temperature;
7. add 40 μL of dd H2O and incubate the plate for 5 minutes at room temperature 
and then transfer samples into a new clean reaction plate.
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Manual
The DyeEx™ 2.0 Spin Kit (QIAGEN), providing the 
combination of gel‑filtration technology with a pre‑hydrated 
microspin format, was used. This procedure is based on 
gel filtration chromatography that separates molecules 
according to molecular weight. The kit uses gel‑filtration 
material consisting of spheres with uniform pores; 
when sequencing reactions are applied onto columns, 
dye terminators diffuse into the pores and are retained 
in the gel‑filtration material, while DNA fragments are 
eluted (Figure 24).
For the purification of sequencing reaction products, the 
protocol described below was followed:
1. the spin column was gently vortexed to resuspended 
the resin;
2. the cap of the column was loosened a quarter turn to 
avoid a vacuum inside the spin column, the bottom 
closure was snapped off, and the spin column was  
then placed in a 2 mL collection tube;
3. a centrifugation at 2700 rpm for 3 minutes was performed;
4. the spin column was carefully transferred to a clean centrifuge tube and the 
sequencing reaction (20 μL) was slowly applied to the gel bed;
5. a centrifugation at 2700 rpm for 3 minutes was performed;
6. the spin column was removed from the microcentrifuge tube: the eluate 
contained the purified DNA.
After sequence products purification, the samples were loaded on ABI PRISM 3730 
(Applied Biosystems).
Figure 24. Separation 
principle of DyeEx™
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Sequencing 
Samples preparation
For DNA sequencing a 48‑capillary 3730 DNA Analyzer (Applied Biosystems) 
instrument was used. Once purified, samples containing the sequencing reactions 
were prepared on a special plate for multi‑channel electrophoresis runs. This plate 
was formed by 96 wells; purified sequences were added in alternate rows since the 
48 capillaries enter simultaneously in different wells. Two microlitres of purified products 
together with 8 μL of deionized formamide were placed in each well. The plate was 
covered with a rubber mat and centrifuged to bring the samples down to the bottom of 
the wells. Samples were denatured at 95 °C for 2 minutes on a thermal cycler and then 
incubated at ‑20 °C for at least 5 minutes.
Samples loading
Before loading the plate in the instrument, the worksheet showing the order of samples 
was entered in the computer. The first step was to appoint the plate with the “bar code” 
present on its side, together with the date of the transaction. The worksheet is a table 
in which rows represent the name of wells and columns the name of the sample, the 
protocol type and the reading type to be used. The plate was then inserted in the 
instrument: the 48 samples placed in alternating columns were analysed first.
Software for sequence analysis
After the electrophoretic run and the acquisition of data by the analyser, each DNA 
fragment sequence could be viewed on the computer screen: the four bases, labelled 
with different fluorophores, were detected and represented as peaks of four colours 
(green for adenine, blue for cytosine, black for guanine and red for thymine). Raw data 
analysis was performed by using the “Sequencing Analysis” software (Figure 25), 
designed to base‑call, trim, display, edit, and print DNA sequencing data generated 
from the genetic analyser; this step allowed to check if the procedure was successful or 
if the electrophoretic run had to be repeated. Moreover, this software provided multiple 
metrics (sample score, read length, signal‑to‑noise values) that help pinpoint the cause 
of data failure.
65
Figure 25. “Sequencing Analysis” interface: the software was used to observe DNA sequences
By using the SeqScape® software (Figure 26), all the variations (deletions, insertions, 
mismatches, heterozygous bases, and heterozygous insertion/deletions) between 
the reference genomic sequence and each subject sample sequence were detected. 
Software examines the quality of each forward and reverse trace and forms an 
accurate consensus call. Variations between the consensus and the reference 
sequence are reported as mutations in the Mutations report. All analysis in SeqScape® 
software occurred in a project; before creating a project, a project template containing 
a reference data group, analysis defaults and display settings was created. Once a 
project was created, the project template was used recurrently.
As for the “Sequencing Analysis” software, the sequence was represented by a 
succession of peaks characterized by four different colours, one for each nucleotide. 
A peak overlap (identified by letter N) showed the presence of two different nucleotides 
in the same position and, therefore, the presence of a variant in the heterozygous 
state. If the alteration was present in the homozygous state, a different peak in 
comparison with the reference sequence was found: however, the change was 
signalled by the software. The existence of an insertion or a deletion in the sample 
was characterized by the presence of a complicated pattern of overlapping peaks from 
the site of the alteration because of a different positioning between the two strands. 
The presence of any genetic variant was always verified also on the complementary 
strand (3’ → 5’).
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Figure 26. SeqScape® interface: the software was used to identify polymorphisms/mutations by 
comparing the DNA fragment of interest with the reference sequence; the arrows represent a 
mutation found in the heterozygous state
C9ORF72 analysis
The GGGGCC hexanucleotide repeat in C9ORF72 was analysed by a specific 
protocol quite different from the usual process based on amplification, purification and 
sequencing of the samples described above.
The pathogenic repeat expansion may not be amplified by a conventional PCR, and 
therefore DeJesus‑Hernandez and colleagues in 2011 (75) developed a repeat‑primed 
PCR assay, resulting in the identification of the pathogenic repeat expansion. All 
reagents used for PCR assay were provided by Roche. Each PCR reaction was 
performed in a total volume of 14 μL (PCR mixture) and involved the use of:
• Roche Fast Start mix (1X)
• Primer Mix
• 7%DMSO
• Q solution (1X)
• 0.18 mM Deaza GTP
• 0.9 mM MgCl2
• DNA
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The primer mix contains 3 different primers (Table 6) and 25 μL of H2O in a total volume 
of 50 μL.
Name Sequence Comment
RP‑PCR‑F1  
(10 μL) 6‑FAM‑AGTCGCTAGAGGCGAAAGC
FAM 
fluorophore
RP‑PCR‑R  
(5 μL) TACGCATCCCAGTTTGAGACGGGGGCCGGGGCCGGGGCCGGGG
RP‑PCR‑Anchor 
(10 μL) TACGCATCCCAGTTTGAGACG
Table 6. Primers for repeat primed PCR
The repeated primer PCR reaction using the genotyping primers previously reported 
was performed on a thermal cycler using an already described, optimized cycling 
program (141). The PCR products were analysed without any purification or sequencing, 
on an ABI PRISM 3730 DNA Analyser and visualized using GeneMapper software.
The special plate for multi‑channel electrophoresis runs was used. Two microlitres of 
PCR products together with 7.5 μL of deionized formamide and 0.5 μL of Liz500 size 
standard were placed in each well of the plate. The samples were denatured at 95 °C 
for 3 minutes on a thermal cycler and then immediately transferred at ‑20 °C for at least 
5 minutes.
Figure 27. A graphical 
representation of primer 
binding for repeat‑primed 
PCR analysis is shown 
in the upper panel. In the 
lower panel, capillary‑
based sequence traces 
of the repeat‑primed PCR 
are shown. Orange lines 
indicate the size markers, 
and the vertical axis 
represents fluorescence 
intensity. A typical saw 
tooth tail pattern that 
extends beyond the 300 
bp marker with a 6 bp 
periodicity is observed 
in the case carrying 
the GGGGCC repeat 
expansion (76).
exon 1
intron 1
anchor primerreverse primer forward primer 
exon 2
FAM
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Results
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Our cohort of patients includes 285 SALS patients (94.4%) and 17 FALS patients 
(5.6%) respectively.
Frequency of SALS and FALS patients
SALS patients
FALS patients
94,40%
5,60%
Figure 28. Percentage distribution of SALS and FALS in our cohort of patients 
In our cohort we identified, overall, 15 cases of C9ORF72 pathological repeat 
expansion. We considered positive to this genetic test only samples characterized 
by an electropherogram containing 19, or more, peaks with an exponential decay; 
the electropherograms of samples without repeat expansion are on the contrary 
characterized by an abrupt cut‑off.
The characterization of ALS causative genes (SOD1, TARDBP, FUS) through 
sequencing allowed us the identification of 18 genetic variants in SALS and 
FALS cases.
Genetic analysis of FALS patients
Direct sequencing analysis of SOD1, TARDBP and FUS genes in 17 FALS patients 
allowed the identification of 9 different genetic variants. Specifically, we detected:
• 1 mutation in SOD1 gene identified in 2 distinct patients;
•  3 different mutations in TARDBP gene identified in 5 distinct patients;
• 2 different mutations in FUS gene identified in 2 distinct patients.
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As for the C9ORF72 assay, 4 patients showed a pathological repeats expansion. 
Our results about FALS patients are summarized in Table 7.
Gene Number of genetic variants %
SOD1 2/17 11.8
TARDBP 5/17 29.4
FUS 2/17 11.8
C9ORF72 4/17 23.5
Table 7. Distribution of identified genetic variants among ALS causative genes in FALS patients 
in our cohort
ALS causative mutations have been found in 76.5% of FALS cases.
FALS
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Figure 29. Schematic representation of FALS mutations distribution
FALS cases include 9 (53%) male subjects and 8 (47%) female subjects, respectively. 
Specifically, the same mutation in SOD1 (G93D) and TARDBP (A382T) was detected in 
2 females. Conversely the carriers of G294V TARDBP are both males and females.
Gene Male (9) Female (8)
SOD1 ‑ 2 (25%)
TARDBP 2 (22.2%) 3 (37.5%)
FUS 1 (11.1%) 1 (12.5%)
C9ORF72 ‑ 4 (50%)
Table 8. Distribution of mutations between sexes
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In 2 FALS female patients analysed, FUS and TARDBP mutated genes were present 
together with C9ORF72 pathological expansion. The first patient harbouring  
FUS/C9ORF72 mutations has a family history of dementia, whereas the  
TARDBP/C9ORF72 patient has a family history of ALS.
Gene Gender Age at onset
Site of 
onset
Mutation/repeats 
number Geographical origin
SOD1
F 33 Lower limb G93D Caltanissetta (Sicily)
F 18 Lower limb G93D Caltanissetta (Sicily)
TARDBP
M 69 Bulbar G294V Catania (Sicily)
M 62 Upper limb G295S Florence (Tuscany)
F 54 Lower limb G294V Catania (Sicily)
F 63 Bulbar A382T Nuoro (Sardinia)
FUS M 49 Lower limb R521C Piacenza (Emilia)
C9ORF72
F 48 Lower limb 28‑40 Macerata (Marche)
F 36 Lower limb 25‑30 Nuoro (Sardinia)
C9ORF72+FUS F 69 Bulbar >30 + R491C Catania (Sicily)
C9ORF72+TARDBP F 44 Upper limb >30 + A382T Sassari (Sardinia)
Table 9. Summary of mutations and clinical characteristics of FALS patients in our cohort
Genetic analysis of SALS patients
Direct sequencing analysis of SOD1, TARDBP and FUS genes in 285 SALS cases 
allowed the identification of 9 different genetic variants. Specifically, we detected:
• 2 different mutations in SOD1 gene found in 2 distinct patients;
• 3 different mutations in TARDBP gene found in 4 distinct patients;
• 3 different mutations in FUS gene found in 3 distinct patients.
Moreover, we identified 11 C9ORF72 pathological repeat expansions. These results 
are summarized in Table 10.
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Gene Number of genetic variants %
SOD1 2/285 0.7
TARDBP 4/285 1.4
FUS 3/285 1.1
C9ORF72 11/282 3.9
Table 10. Distribution of identified genetic variants among ALS causative genes in SALS 
patients in our cohort
Overall, the mutations detected in our cohort of patients explain 7.1% of SALS cases.
SALS
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Figure 30. Schematic representation of SALS mutations distribution
SALS cases include 160 (56.1%) male subjects and 125 (43.9%) female subjects, 
respectively. The distribution of mutations between sexes is summarized in Table 11.
Gene Males (160) Females (125)
SOD1 1 (0.6%) 1 (0.8%)
TARDBP 2 (1.3%) 2 (1.6%)
FUS ‑ 3 (2.4%)
C9ORF72 4 (2.5%) 7 (5.7%)
Table 11. Distribution of mutations between sexes
C9ORF72 analysis of 3 SALS patients (1 male and 2 females) was impossible because 
amplification did not occur.
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Gene Gender Age at onset
Site of 
onset
Mutation/repeats 
number Geographical origin
SOD1
M 46 Upper limb N65S Fano (Marche)
F 43 Lower limb T137A Zambrone (Calabria)
TARDBP
M 60 Upper limb A382T Margno (Lombardy)
M 51 Upper limb A382T Cagliari (Sardinia)
F 46 Upper limb G368S Lodi (Lombardy)
F 69 Lower limb G294V Chiaramonte (Sicily)
FUS
F 37 Respiratory R522G Naples (Campania)
F 33 Bulbar P525L Catania (Sicily)
F 44 Upper limb R521C Bellano (Lombardy)
C9ORF72
M 73 Bulbar 19 Milan (Lombardy)
M 72 Upper limb 21 Bresso (Lombardy)
M 49 Lower limb 25‑35 Seulo (Sardinia)
M 67 Lower limb 19 Pontinia (Lazio)
F 71 Lower limb 19 Milan (Lombardy)
F 60 Lower limb >30 Milan (Lombardy)
F 55 Lower limb >30 San Pietro di Caridà (Calabria)
F 70 Lower limb >30 Cremona (Lombardy)
F 43 Bulbar >30 Scerni (Abruzzo)
F 62 Upper limb >30 Foggia (Puglia)
F 59 Lower limb >30 Palestro (Piedmont)
Table 12. Summary of mutations and clinical characteristics of SALS patients in our cohort
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Selected familial clinical cases
We report the five most interesting FALS cases that we analysed genetically. All the 
selected patients show heterozygous missense mutations. We report also the 
results for relatives who decided to undergo molecular genetic testing. We analysed 
sequentially SOD1, TARDBP, FUS and C9ORF72 both in the proband and in all of the 
mutated proband’s relatives. 
Family 1
We reported the family harbouring the G93D mutation in exon 4 of SOD1 (Figure 31). 
This mutation has been already reported in literature (142,143).
A
Figure 31. Electropherogram of the G93D mutation 
(c.281 G>A) in the SOD1 gene. The arrow indicates 
the presence of mutation.
Organism Amino acid
H.sapiens 74 GPKDEERHVGDLGNVTADKDGVADVSIEDSVISLSGDHCIIGRTLVVHEK 123
C.elegans 95 GPKSEIRHVGDLGNVEAGADGVAKIKLTDTLVTLYGPNTVVGRSMVVHAG 144
S.pombe 74 DRTAAVRHVGDLGNLESDAQGNIKTTFSDSVISLFGANSIIGRTIVIHAG 123
S.cerevisiae 74 APTDEVRHVGDMGNVKTDENGVAKGSFKDSLIKLIGPTSVVGRSVVIHAG 123
D.rerio 74 GPTDSVRHVGDLGNVTADASGVAKIEIEDAMLTLSGQHSIIGRTMVIHEK 123
G.gallus 74 GPKDADRHVGDLGNVTA-KGGVAEVEIEDSVISLTGPHCIIGRTMVVHAK 122
C.lupus 73 GPKDQERHVGDLGNVTAGKDGVAIVSIEDSLIALSGDYSIIGRTMVVHEK 122
B.taurus 72 GPKDEERHVGDLGNVTADKNGVAIVDIVDPLISLSGEYSIIGRTMVVHEK 121
M.musculus 74 GPADEERHVGDLGNVTAGKDGVANVSIEDRVISLSGEHSIIGRTMVVHEK 123
R.norvegicus 74 GPADEERHVGDLGNVAAGKDGVANVSIEDRVISLSGEHSIIGRTMVVHEK 123
M.mulatta 74 GPKDEERHVGDLGNVTAGKDGVAKVSFEDSVISLSGDHSIIGRTLVVHEK 123
P.troglodytes 74 GPKDEERHVGDLGNVTADKDGVADVSIEDSVISLSGDHCIIGRTLVVHEK 123
D.melanogaster 72 APVDENRHLGDLGNIEATGDCPTKVNITDSKITLFGADSIIGRTVVVHAD 121
Table 13. Amino acid homology at codon 93 of the SOD1 protein in different species
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Figure 32. Pedigree of family 1 with a G93D mutation in the SOD1 gene
The index case is a 33‑year‑old woman, unipara, presented with subacute, severe, left 
lower limb pain the day after a normal delivery, followed by relentless progressive 
weakness and wasting of the left leg; at birth, the newborn was healthy. Later, the 
patient developed progressive worsening of her weakness with involvement of the four 
limbs and the bulbar district, and after 2 years had to face severe respiratory failure. 
Five years from onset, the patient is alive, wheelchair‑bound, in ventilatory assistance 
by tracheostomy and in enteral nutrition by gastrostomy. The patient was admitted at 
NEMO and her neurological examination revealed severe weakness – ranging from 
grade 1/5 to 2/5 according to the Medical Research Council (MRC) scale – of both 
upper and lower limb muscles; all deep tendon reflexes were reduced, and plantar 
reflexes were flexor bilaterally. Hoffmann sign was negative bilaterally, and jaw jerk 
reflexes were normal. MRI of the spine was negative. Needle electromyography (EMG) 
showed increased insertional activity, spontaneous activity (fibrillation potentials and 
positive sharp waves), increased amplitude, and long duration motor unit action 
potentials, associated with reduced recruitment in all limbs. Fasciculation potentials 
were diffusely present. The study was interpreted as consistent with lower motor 
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neuronopathy. Comprehensive laboratory tests yielded no abnormal results, except for a 
mild increase of creatine kinase (CK) level (175 U/L; reference range, 30‑150 U/L).
The family of the index case, which included her 
55‑year‑old mother (III:9), her 60‑year‑old father (III:8), 
and a 26‑year‑old brother (IV:8), had positive history 
for motor neuron disease (III:10 and II:3); no clinical 
information was available for the proband’s grandfather 
(II:7). Following the identification of the G93D mutation 
in the proband, other family members decided to 
undergo the genetic analysis within a multidisciplinary 
context. The results of genetic testing are summarized 
in Table 14.
All mutated subjects were clinically investigated and 
only a 60‑year‑old female (III:10) was found affected. 
Neurological examination of the patient revealed diffuse 
fasciculations in both upper and lower limbs with bilateral muscular weakness (grade 
3/5 on the MRC scale) and atrophy of both hands; tendon reflexes in upper and lower 
limbs were reduced. Hoffmann, Babinski, or Chaddock signs were absent. Laboratory 
tests revealed a mild CK level increase (160 U/L). EMG of tibialis anterior, biceps brachii, 
and first dorsal interosseous showed bilaterally a neurogenic pattern: high frequency 
large motor unit potentials, sporadic denervation (fibrillation potentials, positive waves), 
and fasciculations. Transcranial magnetic stimulation of the motor cortex revealed 
normal central conduction time. Forced vital capacity was 96% of predicted. Clinical 
characteristics of all G93D SOD1 mutation carriers are summarized in Table 15.
Subjects Clinical characteristics
III:2 58 year‑old; female; asymptomatic; normal neurological examination; mild increase of CK serum level (160 U/L; reference range, 30‑150 U/L)
III:5 45 year‑old; female; cramps and fasciculations; normal neurological examination; normal CK serum level
III:9 58 year‑old; female; cramps and fasciculations; normal neurological examination; mild increase of CK serum level (158 U/L)
III:10 60 year‑old; female; hand weakness and hypotrophy; mild increase of CK serum level (162 U/L)
III:12 51 year‑old; male; asymptomatic; normal neurological examination; normal CK serum level
IV:7 (proband) 38 year‑old; female; tetraplegic, in ventilatory assistance by tracheostomy and in enteral nutrition by gastrostomy; mild increase of CK serum level (175 U/L)
IV:11 27 year‑old; male; asymptomatic; normal neurological examination; normal CK serum level
Table 15. Clinical characteristics of G93D SOD1 mutation carriers
Subjects SOD1 result
IV:7 G93D
IV:11 G93D
III:2 G93D
III:5 G93D
III:9 G93D
III:10 G93D
III:12 G93D
IV:8 G93G
IV:9 G93G
III:4 G93G
Table 14. Results of molecular 
analysis in all the tested 
family members (affected and 
unaffected) for SOD1 gene
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Family 2
We described a family with the A382T mutation in the TARDBP gene (Figure 33). 
This mutation has already been reported by different authors (106,109).
Figure 33. Electropherogram of the A382T 
mutation in the TARDBP gene (exon 6). 
G nucleotide is wild type whereas A nucleotide 
corresponds to the mutated allele (c. 1144 G>A). 
The arrow indicates the presence of mutation.
G
Organism Amino acid
H.sapiens 381 AAIGWGSASNAGSGS-GFNGGFGSSMDSKS------------SGWGM--- 414
D.rerio 378 AALGWGTGSNSGAASAGFNSSFGSSMESKS------------SGWGM--- 412
G.gallus 381 AAIGWGSASNAGSSS-GFNGGFGSSMDSKS------------SGWGM--- 414
P.troglodytes 381 AAIGWGSASNAGSGS-GFNGGFGSSMDSKS------------SGWGM--- 414
M.mulatta 381 AAIGWGSASNAGSGS-GFNGGFGSSMDSKS------------SGWGM--- 414
M.musculus 381 APLGWGSASNAGSGS-GFNGGFGSSMDSKS------------SGWGM--- 414
C.lupus 381 AAIGWGSASNAGSGS-GFNGGFGSSMDSKS------------SGWGM--- 414
B.taurus 381 AAIGWGSASNAGSGS-GFNGGFGSSMDSKS------------SGWGM--- 414
Table 16. Amino acid homology at codon 382 of the TDP‑43 protein in different species
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Figure 34. Pedigree of the family with the A382T mutation in TARDBP
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The index case (II:2) is a Sardinian 63‑year‑old woman with signs of multi‑district 
involvement of the upper and the lower motor neurons. Diagnosis of ALS was made 
according to El Escorial criteria. This patient initially presented difficulty in slurred 
speech and in swallowing liquids, with a slowly worsening course. Over the following 
months she developed muscle weakness at the right upper limb associated with 
hypotrophy of the hand’s muscles. Recently she showed emotional instability, muscle 
cramps and diffuse fasciculations in all four limbs.
The patient’s family pedigree showed a positive history of motor neuron disease. The 
father of the proband (I:2) died of ALS when 79‑year old. Her son (III:1) is 40 years old 
and was diagnosed with a spinal form of ALS since age 35. Following positive genetic 
test for the presence of the A382T mutation in the proband, we had liked to test for the 
presence of the same mutation the other affected family members. Unfortunately the 
proband’s father (I:2) was already died, whereas the affected proband’s son (III:1) as 
well as the other unaffected daughters were not tested because they live in Sardinia 
and were not interested in genetic testing at the time we offered it. 
Family 3
We reported the family harbouring the G294V mutation in exon 6 of TARDBP 
(Figure 35). This mutation has been already described in a familial case of ALS (103).
Figure 35. Electropherogram of G294V mutation (c.881 G>T) 
in the TARDBP gene. Sequence analysis (reverse strand) 
of the PCR product showed the mutated T (forward strand). 
The arrow indicates the presence of mutation.
A
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Organism Amino acid
H.sapiens 268 RQ-LERSGRFGGN-----------PGGFG---NQGGFGNSRGGGAGLGNN 302
C.elegans 344 QS------------------------------------------------ 345
D.rerio 274 RQMMERAGRFGNG-----------FGGQG---FAGSRSNMGGGGGGSSSS 309
G.gallus 268 RQ-LERGGRFGGN-----------PGGFG---NQGGFGNSRGGGGGLGNN 302
P.troglodytes 268 RQ-LERSGRFGGN-----------PGGFG---NQGGFGNSRGGGAGLGNN 302
M.mulatta 268 RQ-LERSGRFGGN-----------PGGFG---NQGGFGNSRGGGAGLGNN 302
M.musculus 268 RQ-LERSGRFGGN-----------PGGFG---NQGGFGNSRGGGAGLGNN 302
C.lupus 268 RQ-LERSGRFGGN-----------PGGFG---NQGGFGNSRGGGAGLGNN 302
B.taurus 268 RQ-LERSGRFGGN-----------PGGFG---NQGGFGNSRGGGAGLGNN 302
Table 17. Amino acid homology at codon 294 of the TDP‑43 protein in different species
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Figure 36. Pedigree of family 3 with G294V TARDBP mutation
The proband (III:8) was a woman who developed ALS with spinal‑onset when she was 
54 years old and died 2 years later. This patient presented fasciculations initially to the 
abdomen and afterwards to the lower limbs, associated with progressive weakness. A 
few months later she developed difficulty in slurred speech and change in the tone of 
her voice. No cognitive involvement was observed.
The patient’s family pedigree showed a positive history both for motor neuron disease 
and for dementia. Previously, in 2009, the proband’s brother (III:6) developed a 
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bulbar form of ALS and died the following year. Moreover the mother of the proband 
was affected by FTD and other relatives were affected by dementia (I:2; II:3; II:5). 
Other family members underwent genetic testing and only the proband’s daughter 
(IV:4) resulted to be heterozygous for the G294V mutation; however, due to her young 
age (<30‑year‑old), she currently presents no neurological symptoms.
Family 4
We described a family with the R521C mutation in the FUS gene (Figure 37). 
This mutation has already been reported by different authors (99).
Figure 37. Electropherogram of the R521C mutation in the FUS 
gene (c.1561 C>T). This mutation was identified in exon 15. 
Sequence analysis (reverse strand) of the PCR product showed 
the mutated T (forward strand). The arrow indicates the presence 
of mutation.
G
Organism Amino acid
H.sapiens 491 RGGFRGGRG------GGDRGGFGPGKMD--SRGEHRQD--RRERPY 526
D.rerio 507 RGGFRGGR-------GGDRGGFGPGKMD--SRGDHRHD--RRDRPY 541
G.gallus 470 RGNFRGGR-------GGERGGFGPGKMD--SRGDHRQD--RRERPY 504
B.taurus 477 RGGFRGGRG------GGDRGGFGPGKMD--SRGEHRQD--RRERPY 512
M.musculus 483 RGGFRGGRG------GGDRGGFGPGKMD--SRGEHRQD--RRERPY 518
R.norvegicus 483 RGGFRGGRG------GGDRGGFGPGKMD--SRGEHRQD--RRERPY 518
Table 18. Amino acid homology at codon 521 of the FUS protein in different species
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Figure 38. Pedigree of the family with the R521C mutation in the FUS gene
At first neurological examination, the index case, a 49‑year‑old man, showed weakness 
at the left lower limb. Laboratory tests revealed a sharp increase in CK level (900 U/L). 
Needle electromyography (EMG) demonstrated a widespread distribution of axonal 
suffering compatible with neuropathy. Very recently the proband showed progressive 
weakness of all four limbs. No bulbar signs were present, and in particular we did not 
observe slurred speech or difficulty in swallowing liquids and foods. Diagnosis of ALS 
was made according to El Escorial criteria.
The father of the proband (II:7) was affected by ALS and died when he was 58 years 
old. The family members who decided to undergo genetic testing were: III:2; III:4; III:5 
and III:8. Only the proband’s sister (III:8) resulted positive at the genetic test but without 
neurological clinical signs, although she is older than her affected brother. 
Family 5
We described a family with the A382T mutation in the TARDBP gene (Figure 39). 
As mentioned above, this mutation has already been reported by different 
authors (106,109). Moreover the proband has a pathological repeat expansion in the 
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C9ORF72 gene. The amino acid homology among different species for position 382 
in TARDBP gene is presented in Table 16.
Figure 39. Electropherogram of the A382T mutation in the 
TARDBP gene (exon 6). G nucleotide is wild type whereas 
A nucleotide corresponds to the mutated allele (c. 1144 G>A). 
The arrow indicates the presence of mutation.
G
>30 repeats
Figure 40. Electropherogram with more than 30 peaks and an exponential decay 
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Figure 41. Pedigree of the family with the A382T mutation in TARDBP 
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The index case (III:5) is a Sardinian 44‑year‑old woman who developed a spinal form 
of ALS starting with hypotrophy of the right hand. Needle electromyography (EMG) 
demonstrated neurogenic abnormalities, with aspects of denervation and reinnervation 
in various districts, consistent with a widespread suffering of the lower motor neurons. 
Few months later diagnosis of ALS was made. It should be noted that in 2008 the 
proband was submitted to hormonal treatments for in vitro fertilizations (FIVET).
The patient’s family pedigree showed a positive history of motor neuron disease. Both 
II:6 and II:9 had a spinal‑onset of disease with a fast progressive course. They died 
when they were 62 and 54 years old, respectively, after a disease duration of about 
3 years. They were both non‑competitive soccer players. The proband’s father (II:10) 
has refused to undergo genetic testing. Currently he suffers from hypertension and 
hypercholesterolaemia, but he does not present neurological signs. Only III:6 was 
tested and resulted negative both for the A382T TARDBP mutation and for C9ORF72 
pathological repeats expansion. The remaining living siblings of the proband’s father 
(II:1; II:3; II:4; II:5) were not tested because they live in Sardinia and refused to undergo 
genetic testing since they referred to be in healthy status. 
Selected sporadic clinical cases
We report the two most interesting SALS cases that were genetically analysed. 
The first family has two subjects presenting the p.A382T mutation in the homozygous 
state: the index patient with an 8‑year history of sporadic Parkinson’s disease who 
developed ALS and FTLD 6 years later, and his brother without neurological signs 
and symptoms. The amino acid homology among different species for position 382 in 
TARDBP gene is presented in Table 16. The second case is an ALS patient carrying 
a de novo missense mutation in the FUS gene (R522G), who developed the disease 
during her pregnancy.
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Family 6
BA
Figure 42. Electropherogram that allows the identification of the p.A382T (c. 1144 G>A) 
mutation in the homozygous state. A. The arrow indicates the presence of mutation in the 
homozygous state (p.T382T). B. The arrow points to the wild type sequence.
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Figure 43. Pedigree of family 6
A 61‑year‑old man (II:3) complained of progressive stiffness and slowness of 
movement of the left arm associated with bradykinesia and impairment of the 
voice that became soft and monotonous. The diagnosis of akinetic rigid dominant 
Parkinson’s disease was made. After 6 years, he developed progressive weakness 
of the lower limbs with gait impairment and frequent falls. Needle electromyography 
(EMG) demonstrated chronic and active denervation in muscles of the lower limbs; 
a nerve conduction study showed mild amplitude reduction without conduction 
blocks at both legs. Results of the tests were interpreted as consistent with possible 
inflammatory axonal polyneuropathy. Later, the patient developed progressive 
worsening of the weakness in the lower limbs and involvement of both upper limbs; 
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the neurological examination revealed hypophonia, rigidity, and distal weakness of 
both upper‑limb muscles and hypotonia associated with diffuse weakness of both 
lower‑limb muscles, which were also hypotrophic; tendon reflexes were brisk in the 
upper limbs and reduced in the lower limbs. Further neurophysiological analysis 
showed widespread suffering of lower motor neurons in the four limbs. A diagnosis 
of ALS was made. Finally, the patient developed progressive dyspnea requiring non‑
invasive ventilatory support and dysphagia (for solids and liquids). Eight years after 
onset, the patient developed behavioural (apathy) and psychiatric (hallucination) 
symptoms. Neuropsychological examination showed pathological scores consistent 
with behavioural variant FTLD (bvFTLD). One month later, the patient died due to acute 
respiratory failure.
Genetic screening of family members prompted us to clinically evaluate the mutation 
carriers; the 67‑year‑old proband’s brother (II:2) did not show any neurological signs. 
The two heterozygous mutation carriers are III:1, a 31‑year‑old healthy man without 
any neurological signs or symptoms, and III:2, a 36‑year‑old woman unable to hear or 
speak after meningitis infection at 3 years of age. The father and mother of the index 
case were reported to be first cousins; they died at ages 67 and 54 of a liver cirrhosis 
and a tongue tumour, respectively; their DNA was not available for genetic testing, and 
they were reported to have had no signs of motor neuron dysfunction, extrapyramidal 
disorder, or cognitive impairment.
Family 7
Figure 44. Electropherogram of R522G mutation in the FUS 
gene (c.1564 A>G). Sequence analysis (reverse strand) of 
the PCR product showed the mutated G (forward strand). 
The arrow indicates the presence of mutation.
C
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Organism Amino acid
H.sapiens 491 RGGFRGGRG------GGDRGGFGPGKMD--SRGEHRQD--RRERPY 526
D.rerio 507 RGGFRGGR-------GGDRGGFGPGKMD--SRGDHRHD--RRDRPY 541
G.gallus 470 RGNFRGGR-------GGERGGFGPGKMD--SRGDHRQD--RRERPY 504
B.taurus 477 RGGFRGGRG------GGDRGGFGPGKMD--SRGEHRQD--RRERPY 512
M.musculus 483 RGGFRGGRG------GGDRGGFGPGKMD--SRGEHRQD--RRERPY 518
R.norvegicus 483 RGGFRGGRG------GGDRGGFGPGKMD--SRGEHRQD--RRERPY 518
Table 19. Amino acid homology at codon 522 of the FUS protein in different species.
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Figure 45. Pedigree of family 7
A 37‑year‑old female during the last trimester of pregnancy complained of dyspnea, 
especially when she was lying. One year later she developed feeling of breathlessness 
in aloud reading and soon after presented difficulty in slurred speech and in 
swallowing solids. Needle electromyography (EMG) was consistent with ALS diagnosis 
emphasizing the occurrence of denervation potentials at the right deltoid muscle and 
at the bilateral brachial biceps muscles. Two years after onset, the patient is alive, 
in non‑invasive ventilatory assistance and in enteral nutrition by gastrostomy.
The proband’s parents (I:1) as well as proband’s brother (I:2) are healthy. Neither the 
father nor the mother carry the FUS mutation identified in the proband, nor any other 
mutation of genes related to ALS. The proband’s brother (II.1) was tested and resulted 
negative. Accordingly this is one of the few genetically proven cases of FUS mutation 
in a patient with true sporadic ALS (de novo mutation).
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A senataxin case
The clinical features of one patient in our cohort suggested screening for mutation 
the SETX gene. Sequencing all the 26 exons and intron/exon boundaries of the 
SETX gene lead to the identification of a heterozygous missense mutation, L389S 
(c.1166 T>C) in exon 10 (Figure 46). This mutation was previously reported in settings 
different from the Italian populations (121).
Figure 46. Electropherogram of L389S mutation in 
the SETX gene. The arrow indicates the presence 
of mutation.
C
Organism Amino acid
H.sapiens 344 S-YLDDMVTCSQIVYNYNPEKTKKDS--GWRTAICPDYCPNMYEEMETLA 390
D.rerio 311 PEYDDNVVTCSQMVYDCYASKKQGHAPGSSNSGVGSNYV--IYDDMQSLV 358
G.gallus 345 TDYDDEMVTCSQIVYTCNTEKPQKDT--GWKTAICPDYCPNMYEDMQTLA 392
M.musculus 344 P-HFDDMVTCSQIVYNFNPEKTKKDS--GWRSAICPDYCPNMYEEMETLA 390
R.norvegicus 344 P-HFDDMVTCSQIVYNYNPEKTKKDS--GWRSAICPDYCPNMYEEMETLA 390
M.mulatta 344 S-YLDDMVTCSQIVYNYNPEKTKKDS--GWRTAICPDYCPNMYEEMETLA 390
P.troglodytes 344 S-YLDDMVTCSQIVYNYNPEKTKKDS--GWRTAICPDYCPNMYEEMETLA 390
C.lupus 344 S-YSDDMVTCSQIVYNYNPEKTKKDS--GWRSAICPDYCPNMYEEMETLA 390
B.taurus 344 S-YLDDMVTCSQIVYNYNPEKTKKDS--GWRSAICPDYCPNMYEEMETLA 390
Table 20. Amino acid homology at codon 389 of the SETX protein in different species
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Figure 47. Pedigree of the family with the L389S mutation in senataxin
A 24‑year‑old man complained of weakness of the right hand and leg during nine 
months. The first neurological examination showed weakness of the right hand and 
distal right leg, and brisk tendon reflexes. No fasciculation was visible; no cramp was 
reported. Needle EMG demonstrated fibrillation potentials and increased amplitude 
of motor unit action potentials (MUAPs) in distal muscles of the right limbs. A nerve 
conduction study showed multiple conduction blocks at right ulnar and peroneal 
nerves (amplitude reduction by 55% in the arm and by 67% in the leg). The study was 
interpreted as consistent with multi‑focal motor neuropathy (MMN). In 1998, the man 
developed a progressive worsening with involvement of all four limbs. The patient’s 
condition deteriorated and neurological examination revealed distal weakness of both 
upper and lower limb muscles; all tendon reflexes were brisk and plantar reflexes 
were extensor bilaterally; Hoffmann sign was positive bilaterally. MRI of the spine was 
negative. Nerve conduction studies of the four limbs did not detect conduction blocks. 
EMG showed spontaneous activity (fibrillation potentials and positive sharp waves), 
increased amplitude and long duration of MUAPs, associated with reduced recruitment 
in all limbs.
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A wider investigation of familial history let us know that four relatives, living in Germany, 
were affected by motor syndromes with juvenile onset. One uncle (II:4) as well as 
one cousin (III:6) were not available for examination or SETX mutation screening and 
refused to undergo genetic testing. It was impossible to test the maternal grandfather 
(I:3), because he was already dead. Conversely III:7 decided to send us a blood 
sample for genetic testing. We tested also the proband’s mother (II:2), who has 
progressive walking impairment, as well as the proband’s sister, who has just begun 
to develop lower motor neuron signs (III:3). All the available affected relatives resulted 
positive to the test. The proband’s siblings (IV:3; IV:4) resulted to be heterozygous 
for the L389S mutation; however due to their early age they actually presents no 
neurological symptoms.
Genetic counselling 
The results of the genetic tests were communicated to all subjects carrying a mutation 
within a multidisciplinary context, in order to help the proband and their relatives 
understand the uncertainties that may remain after clinical genetic testing.
At this time predictive or presymptomatic testing should be undertaken with caution. 
Specifically, families should consider the limitations of genetic testing, including the fact 
that the mutation in ALS causative genes cannot predict exact age of onset or symptom 
expressivity. In the context of diagnostic testing, detecting a mutation will resolve 
neither issues of reduced penetrance nor clinical heterogeneity.
Discussion
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General considerations
Our cohort of ALS patients is represented by 302 subjects. Globally, our molecular 
analysis explained 10.3% of ALS cases (31/302) with 64.7% (11/17) of familial 
cases and 7.1% (20/285) of sporadic cases. The highest frequency of positive cases 
was obtained in C9ORF72 (5%), followed by TARDBP (2.9%), FUS (1.65%) and 
SOD1 (1.32%). 
The clinical phenotype of FALS cases is usually indistinguishable from SALS. However, 
in comparison with SALS, FALS is characterized by an equal male: female sex ratio, 
an earlier age at onset, and, generally, a longer disease duration. The first signs of 
the disease often occur in the lumbosacral segment, and atypical symptoms may be 
present at onset (22). 
In our mutated population we have found a slight difference in the age of onset 
between SALS cases (mean age 55.5, range between 33 and 73) and FALS cases 
(mean age 49.5 range between 18 and 69) as well as, in FALS patients, a higher rate 
of lower limbs onset (6) compared to other types of onset (3 bulbar and 2 upper limb). 
These results are consistent with literature data (89). Conversely in our FALS cohort we 
have found more female (8) than male (3) mutated patients.
There is considerable evidence of a genetic contribution to familial and sporadic forms 
of ALS and the observation that Mendelian genes are found mutated in subjects with 
no family history is the most direct evidence for this. We provide here an account on 
the genes tested in this study. 
C9ORF72
In our SALS population we found 3.9% of C9ORF72 hexanucleotide repeats expansion 
carriers, who represent our most common mutation. This finding is in agreement with 
what recently reported in literature regarding Italian population. Indeed, Sabatelli and 
colleagues analysed a large cohort of 1757 Italian SALS cases identifying 69 mutation 
carriers (4%) (144).
The identification of the C9ORF72 expansion in apparently sporadic ALS may have 
different explanations, including poor diagnosis in the past, lack of knowledge of 
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family history, mutation carriers in previous generations dying of other diseases prior 
to developing motor neuron degeneration, reduced penetrance of the gene, and even 
varying phenotypic manifestations among mutation carriers within the same family (145). 
The expansion of the hexanucleotide repeat in C9ORF72 gene was recently 
identified as a major cause of both FALS (23%‑47%) and FTD (12%‑29%) cases. 
These percentages derived from the study of DeJesus‑Hernandez (75) and colleagues 
who analysed a cohort of 34 FALS patients and 374 FTD patients derived from three 
well‑characterized patient series diagnosed at the Mayo Clinic Florida (MCF) as well 
as from the study of Byrne et al. (146)  who analysed 386 SALS and 49 FALS in an 
Irish population. In the same years Renton and colleagues (76) analysed 290 SALS 
and 112 FALS in a Finnish population and confirmed these figures (46.4% FALS and 
21% SALS). To further determine the frequency of the hexanucleotide expansion 
in outbred European populations, they screened a cohort of 268 FALS from North 
America (n=198), Germany (n=41), and Italy (n=29), finding that 102 affected 
individuals (38.1%) carried the same hexanucleotide GGGGCC repeated expansion 
within the C9ORF72 gene. The range of C9ORF72 frequencies depends on the origin 
of the population analysed (75,76,146); in our cohort C9ORF72 mutated patients account 
for 23.5% of FALS.
Specifically in Italy, Ratti and colleagues conducted a mutational analysis in a very 
large cohort of 259 FALS and 1275 SALS Italian patients with ALS and ALS‑FTD 
and found that mutations in C9ORF72 account for 23.9% (62/259) of FALS and 
5.2% (66/1275) of SALS cases, respectively (147).
In addition this study revealed that mutational frequency of C9ORF72 was higher in 
FALS (50%) and SALS (10%) patients presenting with concomitant FTD signs (146). In 
our population cognitive impairment was present in 14/302 (4.6%) SALS and none of 
FALS patients; therefore we couldn’t confirm the recent findings that a family history 
of neurodegenerative disease and of cognitive/behavioural impairment makes an 
individual at higher risk of carrying a repeat expansion in C9ORF72. Moreover, we 
detected just one C9ORF72 repeats expansion carrier among our 14 SALS patients 
with Parkinson’s disease and behavioural variant FTLD. A possible overlap with 
Parkinsonism is also suggested by the peculiar phenotype of C9ORF72 repeats 
expansion carriers, which often includes extrapyramidal features and a positive family 
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history for Parkinson’s disease (147). All these observations suggest that C9ORF72 
repeats expansion may contribute to the pathogenesis of a broad spectrum of 
neurodegenerative diseases.
Together with cognitive impairment, bulbar‑onset seems more frequent in patients 
carrying C9ORF72 mutations than in patients carrying TARDBP, SOD1 or unknown 
mutations. Moreover C9ORF72 expansion is reported to be more frequent among 
patients with disease onset >61 years (86). Our results do not confirm these data 
because our C9ORF72 mutated patients developed mainly lower limbs onset (9/15) 
compared with other types of onset and just half of our C9ORF72 carriers are older 
than 60 years.
One of the limits to the clinical utility of C9ORF72 gene testing is the lack of 
knowledge on the minimum number of repeats required to confer a pathological 
phenotype. The repeat unit is six nucleotides long, and in the affected individuals 
the unit expands up to more than several hundred times. It is not clear which is the 
normal range of repeat size in healthy individuals; for sure, fewer than 10 repeats 
are not associated with a pathological phenotype, while more than 30 repeats are. 
However the significance of intermediate repeat sizes (11‑29) is still unknown. 
For this reason, in our study, we decided to consider as pathological also the patients 
with intermediate repeats. 
Regarding the repeats size it is necessary to remember that cytosine (C) methylation 
in CpG dinucleotides is an important epigenetic modification that could lead to gene 
expression silencing as a result of CpG’s hypermethylation. Indeed a direct correlation 
between CpG methylation and repeat size was already observed in other neurological 
disorders (e.g. Friedrich ataxia), in which the degree of methylation gradually increases 
along with the numbers of nucleotide repeats.
A second problem relates to the repeat‑primed PCR method that we used to screen 
ALS and FTD patients. Even though this method is fast and cost‑effective, it does 
not provide an accurate estimate of the number of repeats. Alternatively, Southern 
blot analysis should be used to estimate the number of repeats in expanded repeats 
carriers; however, its application appears to be laborious and too much expensive.
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Finally, somatic heterogeneity is likely to be common in repeat expansion carriers, 
resulting in varying repeat sizes in different tissues from a single patient. As a result, 
repeats sizes determined using DNA extracted from whole blood, that we used for our 
samples, may not adequately reflect the C9ORF72 repeat sizes in a patient’s brain or 
spinal cord tissue and may hamper genotype‑phenotype correlations. 
SOD1
In our SALS cohort we identified 0.7% of SOD1 mutation carriers. This frequency 
of SOD1 mutation in SALS patients is lower than what evaluated by other groups in 
Italian population. Specifically Gellera and colleagues reported 2/44 SOD1 mutated 
carriers who account for 4.5% in the population studied (94). Conversely our data 
are in agreement with results from another Italian study, conducted by Battistini 
on a large cohort of 225 SALS patients that included no SOD1 mutated carrier (96). 
However, it is interesting to note that a wide variability in the SOD1 mutation carriers 
frequency has been reported within the same Italian SALS population (ranging from 
0% to 6.3%) (79,94,148).
This difference could be due to bias in the patient’s selection. Indeed, it is possible 
that SALS are misdiagnosed, so some of them could have been FALS cases instead. 
This may occur for a variety of reasons including decreased penetrance, poor 
diagnosis of ALS in the elderly in previous generations, or incomplete family history. 
Another possibility is that apparently sporadic ALS with SOD1 mutations may be due 
to de novo mutations. It is difficult to determine whether the SOD1 mutations identified 
were due to de novo mutations because seldom DNA samples were available from the 
parents of the SALS cases: given that ALS is predominantly a disease of middle and 
older age groups, the proband’s parents are alive any not longer.
The frequency of SOD1 mutations among familial cases in our cohort is 11.8%. 
This rate is similar to figures based on Chiò’s study made on 22 FALS cases 
(13.6% of all FALS) (79), likely because we have a similar sample size.
Generally, in patients with SOD1 mutations cognitive impairment is very rare (0‑2.6%) 
and bulbar‑onset is observed less frequently (7‑12%) than in non‑SOD1 patients (31); 
age of disease onset is generally higher than in FUS patients but is lower than in other 
non‑SOD1 patients. Our population confirms these literature data about cognitive 
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impairment as well as bulbar‑onset. Indeed we don’t have any SOD1 mutation carriers 
with cognitive impairment and our SOD1 mutated patients all have a spinal‑onset 
of disease (3 lower limbs and 1 upper limbs). Otherwise, age at disease onset in 
our cohort of FALS patients is lower than in FUS mutation carriers; this is probably 
due to the G93D mutation found in our patients, which is associated to a specific 
mild phenotype. Indeed, carriers with long survival time generally survive more than 
20 years after the onset of the disease. In one of our SOD1 carriers, who developed 
the disease during pregnancy, we have also found angiogenin genetic variant 
(IVS1+27 variant in heterozygous state C/T) (149). Likewise we could hypothesize 
that there could be other modifier genes or hormonal condition that influenced the 
phenotypic expression.
TARDBP
In our SALS population we identified 1.4% of TARDBP mutation carriers. This rate 
is higher than mutational frequency reported in other Italian studies. Ticozzi and 
colleagues (150) screened 208 FALS and 188 SALS cases for mutations in exon 6 of the 
TARDBP gene. Their observation that TARDBP mutations account for ca. 0.5% of all 
SALS patients are not in agreement with another screening that analysed 541 SALS 
and 125 FALS patients, respectively, and reported mutations in ca. 2% of sporadic 
cases (103). The discrepancy may reflect the different Italian geographic origin of the 
patients together with the larger number of ALS cases analysed by Corrado and 
colleagues. Overall, we can conclude that our proportion of SALS TARDBP mutated 
cases is closer to the results from Corrado et al. (103).
Our cohort includes 17 FALS patients with a rate of 29.4% (5/17) TARDBP mutation 
carriers. This incidence is completely different from that in previous studies, which 
screened 208 and 125 FALS patients, respectively, and found 13 (6.3%) and 6 (4.8%) 
TARDBP mutation carriers, respectively (103,150). 
This apparent higher incidence of TARDBP mutations in our Italian FALS patients with 
respect to other studies may be influenced by the small sample size as well as by the 
presence of 2 mutated Sardinian and Sicilian patients. Indeed, very recently, it has 
been found that a single missense mutation in TARDBP gene (A382T) accounts for 
approximately one‑third of all ALS cases in the Sardinian population. Furthermore, 
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these ALS patients shared a high‑risk haplotype across the TARDBP locus, indicating 
that they had a common ancestor and were part of a larger kindred (107). Since Sicily 
is as geographically isolated as Sardinia, the incidence of TARDBP mutation carriers 
could be higher than in the rest of Italy. 
Regarding the clinical phenotype, cognitive impairment has been observed in 31% 
of patients with mutations in TARDBP (151). In our cohort of 9 TARDBP mutated patients, 
we found only one patient with bvFTLD; this accounts for 11.1% of all TARDBP 
cases. Millecamps and colleagues supposed the occurrence of TARDBP mutations 
is rare in patients with age of onset >61 years (86), but this assumption has not been 
confirmed in our as well as in other studies (103). Moreover, with a single exception, 
all of the missense mutations identified in this gene are clustered in the glycine‑rich 
C‑terminal region encoded by exon 6. Hence, we decided to analyse only this exon 
in all ALS patients.
FUS
In our study both the rate of SALS FUS mutation carriers (1.05%) and the mean age at 
disease onset (38 years) are very similar to data reported in the study of Sproviero (152). 
Indeed, Sproviero and colleagues reported a molecular screening of the FUS/TLS gene 
in 327 sporadic ALS patients from Southern Italy with a mutational frequency of 1.25%. 
The mean age at disease onset in the ALS mutated patients was significantly lower 
(range: 26‑53; average 39 years) than in the whole cohort (56.77 years), confirming 
that mutations in FUS are associated with an earlier onset of the disease in comparison 
with the general mean age of approximately 60 years reported for ALS (40).
Moreover as far as our population is concerned, there was a slight observed female 
bias among SALS patients with FUS mutations, but this was not statistically significant 
(p=0.083 calculated with Fisher’s test).
In our FALS cohort we found 11.08% of FUS mutation carriers. The frequency of FUS 
mutation in FALS patients is higher than what evaluated by other groups (115,120). In the 
Chiò’s study mutations in the FUS gene accounted for 3.8% of 52 non‑SOD1 and 
non‑TDP‑43 FALS index cases. In the same year, in a cohort of 94 FALS non‑SOD1 
and non‑TDP‑43 mutated patients, Ticozzi estimated that ca. 4% of FALS cases are 
caused by mutation in the FUS gene.
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The higher incidence of FUS mutations in our 10 non‑SOD1 and non‑TDP‑43 mutated 
FALS cases may be due to the small sample size, which could not reflect the situation 
in the population at large. In addition, in our FALS cohort we do not found a difference 
in the male/female distribution of FUS mutations as reported by others (115,120).
Although genotype‑phenotype correlations are not possible for the majority of FUS 
mutations, it has been suggested that substitutions of arginine 521, in particular 
the replacement with a cysteine (R521C), may result in an uncommon phenotype 
characterized by a symmetrical proximal spinal‑onset, with early involvement of the 
axial muscles (115). These observations are in agreement with our population, in which 
we found both in 1 FALS and 1 SALS case with this mutation. These cases have a 
spinal‑onset of disease with an early age at onset and the characteristic phenotype. 
In FUS mutation carriers age of disease onset is consistently lower than in other FALS 
mutated cases, but this findings not confirmed in our cohort, because 2 G93D SOD1 
mutations carriers in the FALS cohort have a younger onset form of disease (18‑ and 
33‑year‑old). Moreover it is important to note that the FALS patient with the presence 
of FUS/C9ORF72 mutation simultaneously has an older age at onset (69‑year‑old). 
This case needs further investigation to correlate a combination genotype with specific 
clinical phenotype (possible presence of other modifier genes).
Senataxin
The high degree of clinical and genetic heterogeneity in the various forms of 
juvenile ALS can make differential diagnosis difficult. Other genetic disorders that 
may mimic juvenile ALS phenotypes include: spinal muscular atrophy, hereditary 
spastic paraplegia, and the hereditary motor neuronopathies/motor forms of 
Charcot‑Marie‑Tooth disease.
We report the first Italian ALS patient with SETX autosomal dominant mutation. 
In this case the late diagnosis of ALS has been established as a consequence of the 
clinical and neurophysiologic picture that were initially consistent with a distal motor 
neuropathy. Indeed, the increment of deep tendon reflexes was not sufficient to rule 
out that hypothesis, since 25% of patients with multi‑focal motor neuropathy reveal 
hyperreflexia (153). However, the progression of muscle wasting, the EMG findings of 
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acute denervation, and the discovery of a positive familial history of motor syndrome 
induced us to go further in genetic investigation, and to test for senataxin gene.
We described the L389S mutation in the SETX gene, which has been previously 
associated with ALS (121). In our SETX family we found different polymorphisms in 
the proband compared with the family members. This intrafamilial variability together 
with other modifier genes could explain the different phenotypic expression of 
the proband (154).
Geographical distribution of mutations
We decided to look for a regional distribution of mutations in our cohort of SALS 
and FALS cases.
Our SALS population of mutated patients (20) includes patients originating from 
different Italian regions. Specifically 9 are from Lombardy, 2 from Sardinia, 2 from Sicily 
and 2 from Calabria. The remaining 5 SALS mutation carriers came from Piedmont, 
Lazio, Abruzzo, Campania and Marche. Differently, our FALS population of mutated 
patients (11) originates mainly from Southern or Central Italian regions. Specifically, 
we have 5 Sicilians and 3 Sardinians. The remaining 3 mutation carries came from 
Tuscany, Emilia and Marche respectively.
The C9ORF72 repeats expansion seems to be more frequent in the Northern than in 
the Southern part of the country, at least in SALS patients. This observation derives 
from the presence of 11 mutated patients, of whom 6 come from Lombardy and 1 from 
Piedmont and the others from Abruzzo, Calabria, Lazio and Sardinia. Conversely, in 
the FALS cases we do not observe the same geographical distribution: 2 originate from 
Marche and Sardinia, while the remaining 2 cases (with coexistent TARDBP or FUS 
mutation) come from Sicily and Sardinia respectively.
Lattante and colleagues suggested a likely regional distribution of the frequency of the 
C9ORF72 analysing 480 SALS and 48 FALS patients from the Central or Southern 
regions of Italy (155). The percentage of SALS with C9ORF72 expansion (2.5%) is 
considerably lower than that reported by another study conducted on North‑Eastern 
Italian regions (156). Indeed Bertolin and colleagues analysed 307 SALS and 46 FALS 
cases and observed 4.5% of C9ORF72 pathological repeats expansion in SALS cases. 
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Regarding FALS cases, we did not find significant differences (9/48 rate 18.8% vs. 
10/46 rate 21.7%). Considering together the presence of C9ORF72 expansions both 
in FALS and SALS, this difference between Northern and Southern Italian regions has 
been confirmed by Chiò and colleagues who analysed 475 patients originating from 
Piedmont and Valle d’Aosta (151). They found 32/475 cases with C9ORF72 mutations 
that account for 6.7% of cases.
Regarding SOD1 we found 4 cases originating from Southern Italy. This finding 
confirms what previously reported in others Italian studies, even though we have 
a small sample size of SOD1 mutation carriers. These studies identified a higher 
frequency of SOD1 G93D carriers in Sicily compared with other Italian regions (31). 
For the FUS mutations carriers we found 4 patients mutated with a uniform 
geographical distribution. Hence, for SOD1 and FUS genes no specific geographical 
association seems to exist.
In our ALS cohort we found a higher frequency mutated patients for TARDBP (2.9%) 
than for the others two genes. This frequency is very similar to that observed by 
Lattante in her study. This similarity is probably due to the population studied. Indeed 
our TARDBP mutated carriers as well as Lattante’s population (155) come mainly from 
Southern Italy (6/9). These observations have been confirmed by Chiò, who screened 
for TARDBP gene 135 Sardinian patients with ALS and found 39 (28.7%) carrying the 
A382T missense mutation (107).
In conclusion, the frequency of mutations in ALS associated genes has been evaluated 
in different epidemiological studies carried out all over the world, whereas it is important 
to assess the frequency of mutations in a specific population – in our case, specifically 
in the Italian population. In fact, the frequency of mutations of a gene can be different in 
different countries or even in different regions of the same country.
Genotype‑phenotype correlation
We reported a detailed profile of clinical and genetics findings of some Italian families 
carrying SOD1, TARDBP or FUS mutations with different intrafamilial phenotypic 
expression. Based on our cohort, we can draw some conclusions. 
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The G93D mutation was identified in a 33‑year‑old pregnant woman who showed 
an unusually fast progression of the disease compared to the paucisymptomatic 
presentation associated with this mutation in the two previously described Italian 
families (142,143). Moreover the remaining mutation carriers did not show the aggressive 
clinical course displayed by the proband.
Hence, to explore the phenotypic heterogeneity within the proband family, we 
investigated the possible relationship between the G93D SOD1 mutation and some 
modifier genes reported to be involved in ALS pathogenesis. Various genes/genetic 
variants could have been tested. Since the involvement of angiogenic factors in ALS, 
albeit controversial, is still attractive (157), we selected ANG and VEGF SNPs for the 
analysis. Then we looked for HFE gene variants implicated in the oxidative stress and 
reported to be associated in some populations with motor neuron degeneration (158). 
Moreover, we decided to investigate PON genes, albeit association studies between 
PON genetic variants and the risk for SALS in different populations reported conflicting 
results (159,160). ALS subjects have been also reported to have a higher median 
homocysteine (Hcy) levels; therefore MTHFR C677T variant was selected because 
linked to an increased level of Hcy (161). Higher Hcy levels seem to also be a possible 
marker of disease progression (162). Finally, alleles E2, E3, and E4 of APOE gene were 
included in our analysis because of their association to some neurodegenerative 
disorders, such as ALS (163).
Results of our study did not identify haplotypes specific to G93D mutation carriers 
or to wild‑type subjects. As unique characteristic of the proband (IV:7), we identified 
the ANG IVS1+27 variant in heterozygous state C/T. To date, little information about 
the role of ANG variants in a SOD1 mutated genetic context are available. In the 
present family, the proband (IV:7) manifested the disease after the delivery, a situation 
that could inherently result in a hypoxic condition: ANG, like VEGF, is expressed in 
response to hypoxia (164,165) and plays a neuroprotective role in motor neurons (166). 
Thus, we might speculate that the patient’s genetic framework, including the G93D 
mutation and the IVS1+27 variation, facilitated the anticipation of onset age and 
contributed to the aggressive clinical course observed in the proband (149).
The A382T TARDBP mutation was identified in a 63‑year old Sardinian woman. 
In this case the proband showed a bulbar‑onset of ALS with a relatively fast 
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progressive course of the disease. In this family we observed the phenomenon of 
anticipation. This condition occurs when the signs and symptoms of some genetic 
conditions tend to become more severe and appear at an earlier age as the disorder is 
passed from one generation to the next. Indeed the proband’s father died of ALS when 
79‑year old whereas the proband’s son showed ALS long before the mother manifested 
the first signs of disease. Anticipation is most often seen with certain genetic disorders 
of the nervous system, such as Huntington disease, but has never been described in 
TARDBP mutation carriers. The A382T mutation has been recently described in 3 ALS 
Italian families, with variable age and site of onset among the family members. Patients 
with ALS carrying A382T TARDBP mutation may develop FTLD (109), but so far we did 
not observe dementia in this family.
We identified another TARDBP mutation, A294V, in a 54‑year old woman. Her family 
has a wide spectrum of clinical symptoms. Some family members showed cognitive 
impairment without signs of ALS (II:3, II:5) conversely other relatives showed a typical 
ALS without any signs of dementia (III:6, III:8, III:13).
The proband’s daughter resulted heterozygous for A294V, but she actually doesn’t 
present any neurological signs, probably because she is very young (<30 years). 
However we are not able to predict whether this subject will develop ALS in the future 
or the clinical features of the disease. 
These two cases of TARDBP mutations support the hypothesis that a mutation is 
not the only factor that determines the clinical course of the disease. Other factors 
must also contribute to phenotype, and it is not yet possible to predict the evolution of 
patients based only on the presence of the mutation or on the age at onset or the rate 
of progression in other family members.
The R521C FUS mutation was identified in a 49‑year old man. Out of 4 family 
members analysed, only the proband’s sister (III:8) resulted positive to the test. She is 
4 years older than her affected brother, but she doesn’t show any neurological signs. 
This different clinical phenotype with the same mutation could be explained by a 
reduced disease penetrance, evident among most affected families with the R521C 
mutation (167). Conversely we could explain these phenotypic differences through 
the neuroprotective effects of estrogen that could account for the later age at onset 
in women. Indeed it has been demonstrated that post‑menopausal women, who 
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are in an estrogen‑deprived state, are at risk for neurodegenerative diseases (168). 
Moreover estrogen loss from natural or surgical menopause has been associated with 
a decline in cognitive function (169) that is reversed by estrogen therapy.
Unfortunately we couldn’t test the paternal grandmother (I:1) as well as proband’s 
father (II:7) because they were already dead. The paternal grandmother was 
probably affected by ALS, because she showed an inability to support her head, likely 
a dropped‑head syndrome, before her last pregnancy. This syndrome, together with 
a young age at onset, is a frequent feature in the R521C mutation carriers (167).
Considerable intrafamilial phenotypic differences were observed in some families 
carrying various mutations in the SOD1, TARDBP and FUS genes. Age and site 
of onset varied between members of a family. The disease duration could also differ, 
as shown in families carrying the G294V TDP‑43 mutation. These data support the 
hypothesis that a mutation is not the only factor that determines the clinical course 
of the disease and introduce the oligogenic disease model.
Oligogenic disease model
Blitterswijk and colleagues report on screening ALS subjects for mutations in five 
pathogenic genes: TARDBP, FUS, SOD1, ANG, and C9ORF72. The authors find 
that a significant proportion of subjects have more than one causative mutation in 
ALS‑associated genes. They detect FUS and TARDBP mutations in combination with 
ANG mutations, and C9ORF72 repeats expansion with TARDBP, SOD1 and FUS 
mutations. The combination of a genetic risk factor with a large effect with another 
mutation with incomplete penetrance fits well the oligogenic disease model (170).
In our cohort we screened 8 index cases and 12 family members for SOD1, TARDBP, 
FUS, C9ORF72 and ANG and we found a second mutation in two familial cases. 
We reported a double mutation carrier belonging to family 5, she is a Sardinian 
woman showing an anticipation of the onset of disease (44‑year‑old) compared with 
affected family members; this clinical feature could be explained by the presence of 
two mutations simultaneously. One of them is A382T TARDBP mutation that accounts 
for one‑third of ALS in Sardinian population, whereas the second one is a pathological 
repeats expansion in the C9ORF72 gene (>30).
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Studying the pedigree of this proband, we observed that the ALS phenotype is 
associated with the paternal line, even if the proband’s father has no neurological signs 
– he should be a A382T obligated carrier. We had the opportunity to study both the 
brother and the mother of the proband, but not yet the father.
The proband’s brother was negative for TARDBP mutations, as well as the mother, and 
we investigated the presence of repeats expansion in C9ORF72 gene in this subjects. 
Indeed the penetrance of the hexanucleotide repeat may be variable, as already 
reported in some families (146), and/or dependent on the presence of other protective/
adverse genetic factors. However the proband’s brother, as well as the proband’s 
mother, resulted negative for presence of pathological repeats expansion (<2).
Moreover we could also speculate that the anticipation presentation of the proband 
disease could be explained also by hormone treatments which she has undergone for 
in vitro fertilization. Indeed the suppression of estrogens, required before beginning an 
in vitro fertilization, could be harmful, because of their neuroprotective role. In addition, 
also the progesterone levels, modified in the hormonal therapy, play an important 
role in stimulating neuron growth and enhancing the re‑myelination of nerve fibres. 
Therefore these hormonal imbalances, together with the double mutations  
TARDBP/C9ORF72, could explain the anticipated presentation in the proband. 
In addition we have data on TARDBP mutation carriers not related to neurological 
phenotype. Indeed we recently found a first family with two subjects presenting the 
p.A382T mutation in the homozygous state (family 6) (171). This mutation is the most 
frequently observed TARDBP mutation, but so far it was always found in heterozygous 
state with only one homozygous case recently reported in Sardinia (Italy) (107). 
Sardinian patients carrying this mutation present with a heterogeneous spectrum 
of ALS phenotypes, ranging from pure ALS to ALS associated with a wide range 
of cognitive impairment.
This family originates from an isolated geographical place in Northern Italy, Valsassina. 
Surprisingly, the two subjects harbouring the mutation in homozygous state display 
different spectra of clinical symptoms: the proband suffers from neurological disease, 
whereas his brother doesn’t manifest any neurological signs. Two other family 
members are carriers of the same mutation in heterozygous state, without neurological 
signs and symptoms. The clinical differences within this family make it impossible 
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for the genetic test to predict clinical outcomes based on genotypic results only. 
Therefore we screened SOD1, FUS, C9ORF72 and ANG in the family members, to 
identify other mutations that could explain this intrafamilial phenotypic heterogeneity. 
The genetic testing of these ALS‑associated genes resulted negative. In this case 
we are not able to explain the different phenotype in two siblings with the same 
A382T mutation, but it is always necessary to consider the variability of penetrance, 
expressivity and modifying factors, such as gene‑gene interactions, as proposed in the 
oligogenic ALS model.
ALS and pregnancy
ALS during pregnancy has been reported since 1967 (172‑174). This association up 
to now has been considered rare and possibly coincidental as no pathogenic 
relationship between the disease and pregnancy has been demonstrated. 
However, hormonal modifications of pregnancy and, specifically, the reduction of 
estrogens are reported as possible risk factors, which may increase the susceptibility 
to ALS during pregnancy (173). Moreover, considering that FALS often have an 
earlier disease onset, it could be expected that women in reproductive age carry 
ALS‑associated mutations (41).
In our cohort of patients we identified a subgroup of women that developed ALS 
during or immediately after pregnancy (1 month) that we define as child‑bearing 
age. In one of them (family 1) we performed a genetic characterization of ALS not 
only for causative genes but also for susceptibility/modifier factors (see genotype‑
phenotype session). The proband showed an unexpected fast‑progressing course 
of the disease compared to the G93D carriers within her family and the two families 
previously described. Unlike the rest of her family, the proband had the ANG variant 
IVS1+27 in heterozygous state C/T (149). In addition, estrogens are known to have a 
potential neuroprotective effect, and, despite data in ALS are scarce and contradictory, 
a decrement of estrogen levels, seen in pregnancy, could unmask ALS, especially in 
patients lacking the complete ability to inactivate superoxide radicals as a result of 
mutations in the SOD1 gene (175).
The second woman who developed ALS in child‑bearing age was affected by the 
first symptoms of disease during the last trimester of pregnancy (family 7). The index 
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case is a R522G FUS mutation carrier, her parents are referred to be healthy; neither 
harbour the mutation; maternity and paternity was confirmed by definite genetic proof, 
with a confidence interval greater than 99.99%. From this evidence, she has a de novo 
mutation. Hence we proved the presence of a FUS mutation in a patient with true 
sporadic ALS. Because the DNA samples of the relatives of sporadic FUS mutation 
carriers has been unavailable in most studies it was difficult to distinguish between 
familial patients with reduced penetrance and true sporadic patients (176).
Much evidence suggests that mutations in FUS are associated with earlier onset of 
ALS than the general mean age of approximately 60 years (177). Moreover the frequency 
of de novo mutations has been often reported for FUS gene, whereas it is rarely 
reported for SOD1 and TARDBP genes (178,179). 
The exact mechanism giving rise this type of mutations is not known, though 
certain spots in the genome are thought to be particularly susceptible to mutation 
(i.e., “mutational hotspots”), presumably because of the surrounding sequence. 
Finally in this case we have both the presence of a de novo mutation and the 
pregnancy condition with a reduced level of the neuroprotective estrogens, which could 
anticipate the clinical manifestation of ALS. After 2 years from the onset of the disease, 
the proband is still alive, so she doesn’t seem to show the rapid clinical progression 
of disease typical of FUS mutated patients.
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Conclusions
In conclusion, in our cohort of 285 SALS and 17 FALS we globally detect 31 mutation 
carriers representing 10.3% of the investigated sample. Several clinical phenotypes 
of ALS may be identified, but no clear boundaries are observed among them, as 
they represent points on a spectrum. Indeed, each one of the ALS‑causing genes 
(SOD1, TARDBP, FUS and C9ORF72) can induce various phenotypes. For example, 
a C9ORF72 expansion mutation can give rise to an ALS phenotype in some family 
members, a frontotemporal dementia phenotype in others, and Parkinsonism or even 
psychosis in others. This phenotypic variability could be identified also in patients 
carrying the same mutation. These considerations indicate that other factors must 
also contribute to the phenotype, and that it is not yet possible to predict the evolution 
of disease patients based on the presence of the mutation only. Recently, in the 
oligogenic disease model, it has been confirmed that the combination of a genetic risk 
factor with a large effect and another mutation with incomplete penetrance could modify 
the phenotypic expression in ALS patients.
Together with the oligogenic disease model other conditions such as pregnancy are 
related to the phenotypic variability. Indeed, estrogens are known to have a potential 
neuroprotective effect, and a decrement of estrogens, typical during pregnancy, could 
unmask ALS, especially in patients lacking the complete ability to inactivate superoxide 
radicals as a result of SOD1 mutations.
All these observations should be considered during genetic counselling. 
Families should consider the limitations of genetic testing, including the fact that the 
mutation in ALS‑causative genes cannot predict exact age at onset of disease or 
symptoms expressivity. Indeed, it is necessary to consider, for example, the variability 
of penetrance, expressivity and modifying factors, such as gene‑gene interactions, 
as proposed in the oligogenic ALS model.
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